Biotech Industry Financials, Performance and Ratios
-
Industry Score
34.8 /100
Rank 80 out of 131 Industries -
Advance/Decline
220/86
-
No. of Companies306
-
Avg. Market Cap3,734
-
Price to Earning Ratio6.58
-
Price to Earning Growth Ratio1.02
-
Price to Book Ratio16.01
-
Return on Equity14.16
-
Return on Capital Employed-
-
Return on Assets8.52
-
Dividend yield 1 year %0.20 %
-
Net Profit Growth Annual YoY %61.57 %
-
Net Profit Growth Qtr YoY %-171.50 %
-
Net Profit Growth Qtr QoQ %-264.93 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
11,456.3
|
22.9
|
L
 2.2%
H
22.5
23.2
|
L
 -1.0%
H
22.2
23.6
|
L
 -4.3%
H
22.2
25.4
|
L
 -5.3%
H
21.3
28.0
|
L
 19.4%
H
18.5
28.0
|
L
 102.4%
H
8.0
28.0
|
L
 -27.6%
H
7.9
35
|
L
H
7.9
37.6
|
| IQVIA |
|
44,456.8
|
270.1
|
L
 0.1%
H
267.3
272.4
|
L
 1.7%
H
263.0
273.9
|
L
 4.0%
H
252.5
273.9
|
L
 61.0%
H
163.4
273.9
|
L
 44.3%
H
154.5
273.9
|
L
 35.6%
H
134.6
273.9
|
L
 5.4%
H
134.6
285.6
|
L
 246.3%
H
70.1
285.6
|
| Nuvation Bio Inc (Class A) |
|
2,141.9
|
6.1
|
L
 0.5%
H
6.0
6.3
|
L
 2.7%
H
5.6
6.3
|
L
 -12.0%
H
5.6
7.2
|
L
 9.7%
H
5.3
7.6
|
L
 89.4%
H
3.0
9.8
|
L
 338.8%
H
1.0
9.8
|
L
 -35.6%
H
1.0
10.5
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
3,421.4
|
26.9
|
L
 3.6%
H
26.0
27.1
|
L
 11.6%
H
23.3
27.1
|
L
 -11.4%
H
23.3
31.6
|
L
 10.5%
H
23.3
31.7
|
L
 116.9%
H
12.2
31.7
|
L
 31.8%
H
6.5
31.7
|
L
 -25.4%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
230.3
|
4.0
|
L
H
4.0
4.2
|
L
 -0.7%
H
4.0
4.3
|
L
 -14.6%
H
4.0
5.1
|
L
 -8.6%
H
3.4
5.1
|
L
 110.4%
H
1.8
5.5
|
L
 -22.2%
H
1.2
5.7
|
L
 -86.5%
H
1.2
33.0
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
4,099.2
|
12.7
|
L
 -0.1%
H
12.5
13.0
|
L
 13.3%
H
10.9
13.2
|
L
 11.8%
H
10.3
13.2
|
L
 128.8%
H
5.0
13.2
|
L
 180.5%
H
2.7
13.2
|
L
 157.6%
H
1.9
13.2
|
L
 -40.0%
H
1.9
22.1
|
L
H
1.9
71.9
|
| Absci Corp |
|
1,838.0
|
10.7
|
L
 9.1%
H
9.8
11.3
|
L
 32.4%
H
7.8
11.3
|
L
 12.2%
H
7.8
11.3
|
L
 44.5%
H
6.7
12.1
|
L
 310.3%
H
2.2
12.1
|
L
 618.8%
H
1.1
12.1
|
L
 3.3%
H
1.1
18.1
|
L
H
1.1
31.5
|
| Adma Biologics Inc |
|
2,197.3
|
9.8
|
L
 3.3%
H
9.5
9.8
|
L
 7.3%
H
8.5
9.8
|
L
 -0.3%
H
8.5
9.9
|
L
 18.1%
H
8.2
10.4
|
L
 -38.3%
H
7.2
20.5
|
L
 175.6%
H
3.1
25.7
|
L
 684.8%
H
1.0
25.7
|
L
 38.6%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
4,478.3
|
28.1
|
L
 0.7%
H
26.7
28.4
|
L
 13.2%
H
24.7
28.8
|
L
 8.0%
H
23.5
28.8
|
L
 -60.0%
H
20.9
91.2
|
L
 -47.5%
H
20.9
91.2
|
L
 35.4%
H
9.1
91.2
|
L
 -81.8%
H
9.1
158.5
|
L
H
9.1
285
|
| Agenus Inc |
|
392.9
|
8.7
|
L
 4.4%
H
8.2
8.8
|
L
 22.0%
H
6.8
8.8
|
L
 7.5%
H
6.7
8.8
|
L
 190%
H
2.9
8.9
|
L
 98.6%
H
2.7
8.9
|
L
 -63.4%
H
1.4
196
|
L
 -92.4%
H
1.4
196
|
L
 -93.8%
H
1.4
196
|
| Change Agents Corp |
|
2.3
|
2.1
|
L
 0.5%
H
2.1
2.2
|
L
 -4.2%
H
1.8
2.2
|
L
 -39.1%
H
1.8
4.7
|
L
 -69.6%
H
1.8
7.3
|
L
 -96.2%
H
1.8
55.4
|
L
 -99.3%
H
1.8
1350
|
L
 -99.9%
H
1.8
3450
|
L
H
1.8
40500
|
| Aldeyra Therapeutics Inc |
|
84.5
|
1.4
|
L
 3.7%
H
1.4
1.4
|
L
 -4.1%
H
1.3
1.5
|
L
 -7.9%
H
1.3
1.6
|
L
 -28.6%
H
1.3
2.5
|
L
 -71.6%
H
1.1
5.9
|
L
 -77.4%
H
1.1
7.2
|
L
 -82.4%
H
1.1
12.0
|
L
 -80.8%
H
1.1
16.7
|
| Alector Inc |
|
224.4
|
2.0
|
L
 4.2%
H
1.9
2.0
|
L
 -9.1%
H
1.8
2.2
|
L
 -14.8%
H
1.8
2.8
|
L
 14.9%
H
1.4
2.8
|
L
 -33.7%
H
1.1
3.4
|
L
 -66.7%
H
0.9
8.9
|
L
 -92.3%
H
0.9
27
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
590.8
|
1.7
|
L
 1.2%
H
1.7
1.7
|
L
 -3.9%
H
1.6
1.8
|
L
 -18.2%
H
1.6
2.2
|
L
 -14.5%
H
1.6
2.3
|
L
 47.4%
H
1.0
4.5
|
L
 -54.0%
H
0.9
5.8
|
L
 -93.2%
H
0.9
27.9
|
L
H
0.9
55
|
| Altimmune Inc |
|
663.3
|
3.4
|
L
 4.3%
H
3.3
3.4
|
L
 3.3%
H
3.2
3.4
|
L
 9.7%
H
3.0
3.6
|
L
 26.3%
H
2.7
3.6
|
L
 -9.8%
H
2.6
6.4
|
L
 33.2%
H
2.1
14.8
|
L
 -77.3%
H
2.1
23.5
|
L
 -99.6%
H
1.5
1050
|
| Alvotech |
|
2,083.8
|
5.8
|
L
 -0.7%
H
5.7
6.0
|
L
 15.6%
H
4.9
6.0
|
L
 31.8%
H
4.7
6.0
|
L
 49.0%
H
3.0
6.0
|
L
 -25.9%
H
2.9
9.3
|
L
 -34.2%
H
2.9
18
|
L
H
2.9
18
|
L
H
2.9
18
|
| Kalaris Therapeutics Inc |
|
77.1
|
3.2
|
L
H
3.2
3.3
|
L
 -1.8%
H
3.0
3.4
|
L
 -21.9%
H
3.0
4.3
|
L
 -31.4%
H
3.0
6.3
|
L
 -28.6%
H
3.0
11.9
|
L
 42.7%
H
0.4
12.9
|
L
 -86.2%
H
0.4
26.4
|
L
H
0.4
49.0
|
| Alx Oncology Holdings Inc |
|
221.2
|
1.6
|
L
 -3.6%
H
1.6
1.7
|
L
 -16.7%
H
1.6
1.9
|
L
 -21.6%
H
1.6
2.1
|
L
 4.6%
H
1.5
2.4
|
L
 32.2%
H
1.1
2.7
|
L
 -68.1%
H
0.4
17.8
|
L
 -97.9%
H
0.4
79
|
L
H
0.4
117.5
|
| Amgen |
|
221,788.9
|
410.2
|
L
 4.3%
H
398.5
413
|
L
 7.5%
H
374.5
413
|
L
 -6.6%
H
374.5
447.0
|
L
 21.5%
H
337.6
447.0
|
L
 43.7%
H
269.8
447.0
|
L
 52.3%
H
249.7
447.0
|
L
 90.5%
H
198.6
447.0
|
L
 136.0%
H
133.6
447.0
|
| AnaptysBio Inc |
|
1,596.5
|
53.9
|
L
 -1.8%
H
50.6
56.0
|
L
 -0.4%
H
50.6
56.0
|
L
 -6.6%
H
50.6
59.1
|
L
 -6.2%
H
49.7
70.9
|
L
 158.7%
H
20.5
73.3
|
L
 214.4%
H
12.2
73.3
|
L
 99.4%
H
12.2
73.3
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,789.6
|
77.9
|
L
 -1.2%
H
76.6
79.3
|
L
 10.7%
H
70
79.4
|
L
 3.4%
H
69.6
79.4
|
L
 -2.0%
H
69.6
87.2
|
L
 -19.5%
H
69.6
97.5
|
L
 31.3%
H
48.2
99.5
|
L
 158.8%
H
22.3
99.5
|
L
 19.6%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
97.0
|
2.8
|
L
 3.3%
H
2.7
2.8
|
L
 -0.4%
H
2.6
2.8
|
L
 -24.8%
H
2.6
3.9
|
L
 -4.1%
H
2.4
3.9
|
L
 -15.5%
H
2.3
5.5
|
L
 -17.9%
H
2.1
5.5
|
L
 -41.8%
H
2.1
6.5
|
L
 -7.3%
H
0.6
8.1
|
| Aptevo Therapeutics Inc |
|
3.3
|
1.9
|
L
 2.2%
H
1.8
1.9
|
L
 2.8%
H
1.7
1.9
|
L
 -31.0%
H
1.4
2.8
|
L
 -60.4%
H
1.4
4.9
|
L
 -94.2%
H
1.4
35.6
|
L
 -100.0%
H
1.4
287179.2
|
L
 -100.0%
H
1.4
12940587.7
|
L
 -100.0%
H
1.4
52102512
|
| AquaBounty Tech Inc |
|
5.6
|
1.1
|
L
 -1.8%
H
1.1
1.2
|
L
 -5.2%
H
1.1
1.2
|
L
 -16.8%
H
1.0
1.4
|
L
 16.0%
H
0.9
1.6
|
L
 -29.2%
H
0.8
3.0
|
L
 -77.7%
H
0.5
6.1
|
L
 -98.7%
H
0.5
90
|
L
H
0.5
610
|
| Arvinas Inc |
|
556.4
|
8.5
|
L
 2.5%
H
8.3
8.6
|
L
 1.3%
H
8.1
8.6
|
L
 -9.1%
H
8.1
9.7
|
L
 11.0%
H
7.5
9.7
|
L
 13.2%
H
7.0
14.5
|
L
 -63.2%
H
5.9
53.1
|
L
 -90.9%
H
5.9
97.3
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
10,150.5
|
71.9
|
L
 4.5%
H
68.1
72.4
|
L
 -10.9%
H
64.5
83.6
|
L
 -17.5%
H
64.5
90.2
|
L
 -12.2%
H
64.5
95.5
|
L
 134.2%
H
30.7
95.5
|
L
 163.9%
H
9.6
95.5
|
L
 15.2%
H
9.6
95.5
|
L
 896.7%
H
1.2
95.5
|
| LeonaBio Inc |
|
57.0
|
6.1
|
L
 -4.4%
H
6.0
6.8
|
L
 -19.0%
H
6.0
7.7
|
L
 -21.2%
H
6.0
8.4
|
L
 -26.0%
H
6.0
10.1
|
L
 56.3%
H
3.6
14.2
|
L
 -69.8%
H
2.2
43.0
|
L
 -93.8%
H
2.2
166.5
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
2,218.0
|
16.7
|
L
 0.4%
H
16.6
16.8
|
L
 1.6%
H
16.0
17.2
|
L
 0.1%
H
15.9
17.2
|
L
 1.3%
H
14.4
19.3
|
L
 28.2%
H
10.3
19.3
|
L
 101.6%
H
4.7
19.3
|
L
 -26.4%
H
4.1
34.0
|
L
 682.6%
H
2.0
34.0
|
| Aura Biosciences Inc |
|
668.9
|
6.5
|
L
 1.4%
H
6.3
6.5
|
L
 -8.0%
H
6.3
7.1
|
L
 -17.3%
H
6.3
8.1
|
L
 1.7%
H
6.3
8.4
|
L
 6.1%
H
4.7
9.5
|
L
 -30.1%
H
4.3
12.4
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
518.1
|
26.5
|
L
 -0.5%
H
26.2
27.6
|
L
 -10.8%
H
26.2
30.0
|
L
 -29.6%
H
26.2
38.9
|
L
 -11.7%
H
26.2
39.5
|
L
 76.9%
H
14.4
39.5
|
L
 44.3%
H
1.4
61.1
|
L
 -64.4%
H
1.4
79.4
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
1,065.9
|
16.8
|
L
 0.1%
H
16.6
17.2
|
L
 -7.8%
H
16.2
18.2
|
L
 -21.5%
H
16.2
22.4
|
L
 -0.4%
H
16.2
25
|
L
 125.9%
H
7.3
28
|
L
 -96.3%
H
6.6
1134.5
|
L
 -96.9%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
229.0
|
2.5
|
L
 2.9%
H
2.4
2.5
|
L
 -5%
H
2.3
2.6
|
L
 -23.8%
H
2.3
3.7
|
L
 -9.5%
H
2.3
3.7
|
L
 -70.8%
H
2.3
10.4
|
L
 -64.6%
H
2.3
14.4
|
L
 -85.8%
H
2.3
23.7
|
L
 -5.4%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
10,638.5
|
203.1
|
L
 -1.2%
H
202.5
207.0
|
L
 -6.2%
H
201.9
216.5
|
L
 -2.3%
H
197.1
229.6
|
L
 -18.9%
H
197.1
253
|
L
 75.2%
H
114.9
260.2
|
L
 171.8%
H
55.0
260.2
|
L
 550.8%
H
20.6
260.2
|
L
 2527.4%
H
1.9
260.2
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.8
|
L
 -4.7%
H
0.8
0.9
|
L
 3.9%
H
0.8
0.9
|
L
 -14.7%
H
0.8
1.1
|
L
 -23.6%
H
0.8
1.1
|
L
 -25.7%
H
0.5
1.4
|
L
 -47.1%
H
0.5
2.6
|
L
 -89.3%
H
0.5
9.0
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
19.6
|
10.1
|
L
 7.1%
H
8.5
10.1
|
L
 -9.0%
H
8.5
11.1
|
L
 28.0%
H
7.4
12.2
|
L
 -8.1%
H
6.5
15.5
|
L
 -69.1%
H
3.0
49.6
|
L
 -92.8%
H
3.0
176
|
L
 -99.3%
H
3.0
1463.5
|
L
 -99.9%
H
3.0
17759.8
|
| Argen X SE (ADR) |
|
60,295.7
|
963.8
|
L
 -2.5%
H
963.5
986.8
|
L
 -2.7%
H
963.5
1003.8
|
L
 -7.3%
H
963.5
1072.8
|
L
 9.8%
H
826.4
1072.8
|
L
 30.8%
H
661.9
1072.8
|
L
 90.7%
H
327.7
1072.8
|
L
 204.6%
H
249.5
1072.8
|
L
H
17.3
1072.8
|
| BridgeBio Pharma Inc |
|
13,534.0
|
69.2
|
L
 4.0%
H
66.6
69.8
|
L
 -4.4%
H
65.8
72.4
|
L
 -15.1%
H
65.8
82.5
|
L
 4.5%
H
65.8
93.4
|
L
 32.2%
H
48.8
93.4
|
L
 156.7%
H
21.6
93.4
|
L
 38.0%
H
5.0
93.4
|
L
H
5.0
93.4
|
| BioCardia Inc |
|
15.9
|
1.1
|
L
 -2.8%
H
1.0
1.1
|
L
 -11.8%
H
1.0
1.4
|
L
 4.0%
H
1.0
1.4
|
L
 8.3%
H
0.8
1.4
|
L
 -9.5%
H
0.8
1.8
|
L
 -81.6%
H
0.8
23.3
|
L
 -97.7%
H
0.8
59.4
|
L
 -99.4%
H
0.8
2073.6
|
| Biocryst Pharma Inc |
|
2,243.6
|
8.8
|
L
 0.2%
H
8.7
9.0
|
L
 6.7%
H
8.0
9.0
|
L
 -8.1%
H
8.0
10.2
|
L
 -2.3%
H
8.0
11.2
|
L
 14.0%
H
6
11.2
|
L
 22.6%
H
4.0
11.3
|
L
 -42.7%
H
4.0
20.0
|
L
 87.2%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
35.6
|
4.1
|
L
 -1.5%
H
3.9
4.4
|
L
 14.9%
H
3.5
4.4
|
L
 0.5%
H
3.4
4.4
|
L
 41.0%
H
2.9
4.4
|
L
 -55.3%
H
2.6
14.7
|
L
 -100.0%
H
2.6
9540
|
L
 -100.0%
H
2.6
18526.5
|
L
 -100.0%
H
2.6
80097.7
|
| Black Diamond Therapeutics Inc |
|
113.8
|
2.0
|
L
 1.5%
H
1.9
2
|
L
 -2.5%
H
1.9
2.0
|
L
 -10.4%
H
1.9
2.3
|
L
 19.3%
H
1.6
2.3
|
L
 -39.6%
H
1.6
4.9
|
L
 -41.8%
H
1.2
7.7
|
L
 -79.2%
H
1.2
10.0
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
2,678.2
|
25.9
|
L
 2.7%
H
25.1
26.5
|
L
 7.5%
H
22.7
26.5
|
L
 -12.9%
H
22.7
31.5
|
L
 -24.1%
H
22.7
38.3
|
L
 6.6%
H
20.2
38.3
|
L
 3.9%
H
13.5
49.5
|
L
 -72.7%
H
13.5
100.1
|
L
H
13
138.5
|
| BioVie Inc |
|
13.9
|
1.6
|
L
H
1.6
1.7
|
L
 -20.5%
H
1.6
1.9
|
L
 -16.4%
H
1.6
2.5
|
L
 -7.4%
H
0.8
3.8
|
L
 -12.4%
H
0.8
3.8
|
L
 -99.4%
H
0.8
582
|
L
 -99.8%
H
0.8
1438
|
L
 -100.0%
H
0.8
5625
|
| Biomarin pharma Inc - Registered Shares |
|
12,266.8
|
63.4
|
L
 -1.1%
H
63.4
64.8
|
L
 -4.6%
H
63.4
66.2
|
L
 -5.0%
H
63.4
67.7
|
L
 15.9%
H
55.0
71.0
|
L
 16.6%
H
49.3
71.0
|
L
 -26.5%
H
49.3
99.6
|
L
 -18.9%
H
49.3
117.8
|
L
 -35.1%
H
49.3
131.9
|
| Bionano Genomics Inc |
|
21.4
|
1.8
|
L
 -0.6%
H
1.8
1.9
|
L
 36.8%
H
1.3
2.2
|
L
 51.7%
H
1.2
2.2
|
L
 59.7%
H
1
2.2
|
L
 1.7%
H
1
2.2
|
L
 -38.9%
H
0.1
11.6
|
L
 -96.5%
H
0.1
62.8
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
382.0
|
11.0
|
L
 0.6%
H
10.6
11.4
|
L
 -9.4%
H
10.6
12.4
|
L
 -18.8%
H
10.6
13.6
|
L
 -9.9%
H
10.6
14.3
|
L
 -18.6%
H
9.9
16.8
|
L
 271.2%
H
2.7
17.2
|
L
 -82.8%
H
1.9
81.3
|
L
 -96.7%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
9.8
|
1.2
|
L
H
1.2
1.2
|
L
 9.0%
H
1.0
1.2
|
L
 6.1%
H
1.0
1.2
|
L
 -0.8%
H
1.0
1.3
|
L
 -39.2%
H
1.0
2.3
|
L
 -98.8%
H
1.0
173.5
|
L
 -100.0%
H
1.0
2742.5
|
L
 -100.0%
H
1.0
22532.5
|
| BioNTech SE (ADR) |
|
25,339.0
|
100.9
|
L
 2.9%
H
97.5
102.2
|
L
 2.0%
H
95.3
102.2
|
L
 -13.5%
H
95.3
116.9
|
L
 11.0%
H
88.2
120.3
|
L
 4.8%
H
79.5
124
|
L
 -5.2%
H
76.5
131.5
|
L
 -70.4%
H
76.5
374.6
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
423.9
|
2.5
|
L
 1.6%
H
2.5
2.6
|
L
 -14.1%
H
2.5
2.9
|
L
 -20.1%
H
2.5
3.8
|
L
 -12.0%
H
2.5
3.8
|
L
 14.2%
H
2
4.2
|
L
 -84.4%
H
1.0
26.4
|
L
 -79.8%
H
0.6
26.4
|
L
H
0.6
26.4
|
| Candel Therapeutics Inc |
|
906.7
|
11.9
|
L
 5.7%
H
11.2
12.0
|
L
 11.0%
H
10.4
12.0
|
L
 -9.8%
H
9.9
14
|
L
 42.6%
H
8.4
14
|
L
 146.4%
H
4.4
14
|
L
 939.5%
H
0.7
14.6
|
L
 40.6%
H
0.7
14.6
|
L
H
0.7
14.8
|
| CalciMedica Inc |
|
12.8
|
1.9
|
L
 0.5%
H
1.8
2.0
|
L
 -6.5%
H
1.8
2.1
|
L
 -34.6%
H
1.8
3
|
L
 -50.5%
H
1.8
5.8
|
L
 -87.6%
H
1.8
36
|
L
 -86.4%
H
1.8
41.9
|
L
 -99.2%
H
1.8
263.9
|
L
H
1.8
2651.6
|
| Tvardi Therapeutics Inc |
|
20.9
|
1.6
|
L
 -2.5%
H
1.6
1.7
|
L
 -14.2%
H
1.6
1.8
|
L
 -15.6%
H
1.6
2
|
L
 -40.3%
H
1.5
5.7
|
L
 -95.9%
H
1.5
43.7
|
L
 -97.5%
H
1.5
67.3
|
L
 -99.7%
H
1.5
681.5
|
L
 -99.4%
H
1.5
1067.3
|
| C4 Therapeutics Inc |
|
407.2
|
3.3
|
L
 0.3%
H
3.3
3.4
|
L
 -3.5%
H
3.2
3.6
|
L
 -17.3%
H
3.2
4.3
|
L
 -20.2%
H
3.2
5.2
|
L
 4.8%
H
1.7
5.2
|
L
 51.1%
H
1.1
11.9
|
L
 -93.4%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
235.9
|
2.5
|
L
 2.1%
H
2.4
2.5
|
L
 0.4%
H
2.4
2.5
|
L
 -5.0%
H
2.4
2.9
|
L
 23.9%
H
2.0
2.9
|
L
 87.2%
H
1.3
3.2
|
L
 154.1%
H
0.5
3.2
|
L
 -60.5%
H
0.5
7.5
|
L
 -62.8%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
93.2
|
1.0
|
L
 -2%
H
1.0
1.0
|
L
 -3.0%
H
1.0
1.1
|
L
 -2%
H
1.0
1.1
|
L
 -32.4%
H
0.9
1.8
|
L
 -30%
H
0.6
2.1
|
L
 -23.4%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Celldex Therapeutics Inc |
|
2,631.5
|
33.5
|
L
 -11.6%
H
30.4
38.4
|
L
 -14.5%
H
30.4
41.6
|
L
 -17.0%
H
30.4
42.1
|
L
 3.3%
H
30.4
45.1
|
L
 36.2%
H
22.1
45.1
|
L
 27.7%
H
14.4
53.2
|
L
 -35.7%
H
14.4
57.2
|
L
 -39.9%
H
1.5
75.3
|
| Co-Diagnostics Inc |
|
7.5
|
1.1
|
L
 6.9%
H
1.0
1.1
|
L
 -2.7%
H
0.9
1.2
|
L
 -10.7%
H
0.9
1.3
|
L
 -68.0%
H
0.9
4.6
|
L
 -91.8%
H
0.9
46.5
|
L
 -96.6%
H
0.9
66.9
|
L
 -99.6%
H
0.9
327
|
L
H
0.9
929.7
|
| Z Squared Inc |
|
147.9
|
2.8
|
L
 5.7%
H
2.6
2.8
|
L
 1.1%
H
2.1
2.9
|
L
 -23.6%
H
2.1
4.6
|
L
 -83.3%
H
2.1
16.6
|
L
 -79.9%
H
2.1
21.4
|
L
 -85.2%
H
2.1
27.6
|
L
 -71.9%
H
2.1
242.6
|
L
H
2.1
242.6
|
| Cogent Biosciences Inc |
|
5,662.1
|
32.6
|
L
 2.0%
H
32.1
32.9
|
L
 -2.3%
H
31.4
33.9
|
L
 -11.2%
H
31.4
37.7
|
L
 -5.5%
H
31.4
43.4
|
L
 172.6%
H
11.6
43.7
|
L
 217.7%
H
3.7
43.7
|
L
 271.2%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Coya Therapeutics Inc |
|
124.3
|
5.3
|
L
 7.1%
H
4.9
5.4
|
L
 14.2%
H
4.5
5.4
|
L
 8.8%
H
4.3
5.4
|
L
 7.7%
H
3.9
6.2
|
L
 -3.6%
H
3.7
7.8
|
L
 30.5%
H
3.2
10.7
|
L
H
3.2
10.7
|
L
H
3.2
10.7
|
| Caribou Biosciences Inc |
|
143.7
|
1.3
|
L
 3.1%
H
1.3
1.4
|
L
 3.9%
H
1.3
1.4
|
L
 -19.3%
H
1.3
1.8
|
L
 -18.3%
H
1.3
2.1
|
L
 -20.7%
H
1.3
3.5
|
L
 -74.5%
H
0.7
8.3
|
L
 -94.5%
H
0.7
26.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
229.7
|
1.9
|
L
 1.6%
H
1.9
2.0
|
L
 -5.0%
H
1.8
2.0
|
L
 1.6%
H
1.8
2.3
|
L
 78.3%
H
1.0
2.3
|
L
 68.8%
H
0.9
2.3
|
L
 101.1%
H
0.7
3.1
|
L
 -53.0%
H
0.5
5.0
|
L
H
0.5
8.5
|
| Curis Inc |
|
2.4
|
1
|
L
 2.0%
H
1.0
1.1
|
L
 -10.7%
H
1.0
1.2
|
L
 -36.7%
H
1.0
1.7
|
L
 -88.1%
H
1.0
11.4
|
L
 -97.1%
H
1.0
34.9
|
L
 -99.4%
H
1.0
349.8
|
L
 -100.0%
H
1.0
3400
|
L
 -100.0%
H
1.0
7440
|
| CorMedix Inc |
|
606.4
|
7.8
|
L
 0.1%
H
7.7
7.8
|
L
 -1.4%
H
7.6
7.9
|
L
 -5.1%
H
7.6
8.7
|
L
 -10.3%
H
7.1
9.1
|
L
 -30.5%
H
6.1
13.0
|
L
 116.1%
H
2.6
17.4
|
L
 68.8%
H
2.6
17.4
|
L
 -47.8%
H
0.9
18.8
|
| CRISPR Therapeutics AG |
|
5,707.8
|
59.0
|
L
 1.2%
H
57.6
60.7
|
L
 11.5%
H
51.5
60.7
|
L
 -0.8%
H
51.3
61.6
|
L
 9.1%
H
45.9
63.5
|
L
 -5.3%
H
44.1
78.5
|
L
 28.2%
H
30.0
91.1
|
L
 -49.7%
H
30.0
122.3
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
73.6
|
5.3
|
L
 0.6%
H
4.9
5.3
|
L
 7.5%
H
4.6
5.6
|
L
 6.7%
H
4.6
5.6
|
L
 -16.3%
H
4.6
7
|
L
 -19.4%
H
4.6
8.3
|
L
 -0.8%
H
3.6
12.0
|
L
 -48.9%
H
3.6
12.0
|
L
 211.2%
H
1.6
17.9
|
| Cue Biopharma Inc |
|
224.5
|
30.9
|
L
 9.3%
H
25.5
32.4
|
L
 1.2%
H
23.8
41.5
|
L
 28.9%
H
22.6
41.5
|
L
 8.6%
H
22.6
45.5
|
L
 53.3%
H
5.0
45.5
|
L
 -56.5%
H
5.0
97.5
|
L
 -92.6%
H
5.0
552.6
|
L
H
5.0
950.7
|
| Cadrenal Therapeutics Inc |
|
4.0
|
1.1
|
L
 2.8%
H
1.1
1.1
|
L
 5.7%
H
1.0
1.2
|
L
 -30.4%
H
1
2.3
|
L
 -68%
H
1
3.9
|
L
 -91.5%
H
1
14.6
|
L
 64.7%
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
17.4
|
2.4
|
L
 -4.0%
H
2.4
2.6
|
L
 -2.9%
H
2.4
2.9
|
L
 10.2%
H
2.1
3.0
|
L
 56.6%
H
1.4
3.0
|
L
 -10.2%
H
1.4
3.6
|
L
 -43.3%
H
1.4
10.2
|
L
 -95.2%
H
1.4
52.8
|
L
H
1.4
736
|
| Compass Pathways PLC (ADR) |
|
2,046.7
|
14.8
|
L
 -1.5%
H
14.6
15.4
|
L
 1.7%
H
13.7
15.6
|
L
 10.9%
H
12.7
15.9
|
L
 18.0%
H
10.6
15.9
|
L
 201.6%
H
4.8
15.9
|
L
 85.7%
H
2.3
15.9
|
L
 -53.3%
H
2.3
49.5
|
L
H
2.3
61.7
|
| DiaMedica Therapeutics Inc |
|
419.5
|
7.8
|
L
 7.2%
H
7.3
7.8
|
L
 18.8%
H
6.4
7.8
|
L
 19.3%
H
6.2
7.8
|
L
 33.0%
H
5.8
8.5
|
L
 14.1%
H
5.2
10.4
|
L
 159.3%
H
1.9
10.4
|
L
 95.0%
H
1.1
10.4
|
L
 97.5%
H
1.1
13.8
|
| Denali Therapeutics Inc |
|
3,452.7
|
21.6
|
L
 5.5%
H
20.5
21.8
|
L
 1.8%
H
19.4
21.8
|
L
 -13.3%
H
19.4
25.3
|
L
 -7.3%
H
19.4
27.3
|
L
 69.4%
H
12.6
27.3
|
L
 -4.0%
H
10.6
33.3
|
L
 -59.4%
H
10.6
56.1
|
L
H
10.6
93.9
|
| Bright Minds Biosciences Inc |
|
595.3
|
60.7
|
L
 2.0%
H
60.2
62.5
|
L
 -4.3%
H
57.6
62.5
|
L
 -21.6%
H
57.6
82.5
|
L
 0.0%
H
57.6
87
|
L
 13.9%
H
48.9
123.8
|
L
 3347.2%
H
0.9
123.8
|
L
 103.6%
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
823.6
|
13.2
|
L
 4.9%
H
12.4
13.3
|
L
 -2.7%
H
12.1
13.5
|
L
 -12.2%
H
12.1
16.0
|
L
 5.8%
H
11.4
16.1
|
L
 117.5%
H
5.3
17.3
|
L
 448.3%
H
2.0
17.3
|
L
 -15.8%
H
1.9
26.3
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
198.5
|
7.2
|
L
 10.6%
H
6.6
7.3
|
L
 4.8%
H
6.4
7.3
|
L
 -18.8%
H
6.4
8.8
|
L
 5.6%
H
6.4
9.6
|
L
 50.4%
H
3.5
9.6
|
L
 1743.6%
H
0.3
19.4
|
L
 -42.4%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dyne Therapeutics Inc |
|
3,200.8
|
17.1
|
L
 0.1%
H
17.1
17.6
|
L
 -7.5%
H
16.8
18.6
|
L
 -34.3%
H
16.8
26.7
|
L
 -13.4%
H
16.8
27.3
|
L
 30.5%
H
11.9
27.3
|
L
 84.9%
H
6.4
47.5
|
L
 6.1%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
448.5
|
2.9
|
L
 3.2%
H
2.8
2.9
|
L
 6.6%
H
2.6
2.9
|
L
 -6.1%
H
2.6
3.5
|
L
 8.6%
H
2.5
3.8
|
L
 3.2%
H
1.7
4.5
|
L
 -63.5%
H
0.9
11.7
|
L
 -95.0%
H
0.9
62.4
|
L
 -80.5%
H
0.9
100.0
|
| Eloxx Pharma |
|
57.5
|
16.7
|
L
 -2.7%
H
16.4
17.6
|
L
 2.6%
H
16.2
19.0
|
L
 -20.3%
H
13.8
23
|
L
 19.7%
H
10
23.4
|
L
 311.1%
H
8.2
23.4
|
L
 244.2%
H
0
23.4
|
L
 -76.5%
H
0
75.6
|
L
 -89.3%
H
0
984
|
| Elicio Therapeutics Inc |
|
49.1
|
1.9
|
L
 -2.1%
H
1.8
1.9
|
L
 -6.5%
H
1.7
2.0
|
L
 -38.5%
H
1.7
3.1
|
L
 -51.4%
H
1.7
5.4
|
L
 -83.5%
H
1.7
16
|
L
 -76.6%
H
1.7
16
|
L
 -98.1%
H
1.7
107.5
|
L
H
1.7
263
|
| Enliven Therapeutics Inc |
|
3,530.9
|
48.2
|
L
 -1.4%
H
47.7
49.1
|
L
 -11.5%
H
47.7
54.5
|
L
 -19.4%
H
47.7
62
|
L
 6.9%
H
45.0
62.3
|
L
 154.2%
H
14.8
62.3
|
L
 278.9%
H
9.8
62.3
|
L
 184.8%
H
3.9
62.3
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
816.2
|
14.2
|
L
 4.2%
H
13.6
14.3
|
L
 -2.4%
H
13.4
14.7
|
L
 -17.8%
H
13.1
18.3
|
L
 24.1%
H
11.4
18.3
|
L
 515.2%
H
1.5
18.3
|
L
 436.2%
H
1.1
18.3
|
L
 -6.7%
H
1.1
20.9
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
11.4
|
0.7
|
L
 -5.8%
H
0.6
0.7
|
L
 -24.4%
H
0.6
0.9
|
L
 -55.8%
H
0.6
1.7
|
L
 4.8%
H
0.4
7.6
|
L
 -37.5%
H
0.4
7.6
|
L
 -58.6%
H
0.4
7.6
|
L
 -94.3%
H
0.4
11.6
|
L
 -99.1%
H
0.4
74.8
|
| Enochian Biosciences Inc |
|
-
|
2.2
|
L
 -3.0%
H
2.2
2.7
|
L
 2.8%
H
2.1
2.7
|
L
 3.2%
H
2.1
2.9
|
L
 -41.0%
H
1.9
4.8
|
L
 1138.9%
H
0.1
5.0
|
L
 596.9%
H
0.1
5.0
|
L
 -68.4%
H
0.1
13.8
|
L
 45.8%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
8.4
|
0.4
|
L
 2.4%
H
0.4
0.4
|
L
 -10.4%
H
0.4
0.5
|
L
 16.2%
H
0.4
0.5
|
L
 59.3%
H
0.2
1.0
|
L
 -79.8%
H
0.2
2.8
|
L
 -73.0%
H
0.1
9.9
|
L
 -100.0%
H
0.1
1680
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
122.4
|
1.9
|
L
 1.6%
H
1.8
2.0
|
L
 -8.1%
H
1.8
2.1
|
L
 -16.5%
H
1.8
2.7
|
L
 -36.7%
H
1.8
3.5
|
L
 32.2%
H
0.8
3.5
|
L
 141.3%
H
0.3
3.5
|
L
 -70.4%
H
0.3
7.1
|
L
H
0.3
27.1
|
| Evogene Ltd |
|
7.7
|
0.5
|
L
 6.5%
H
0.5
0.5
|
L
 -2%
H
0.5
0.5
|
L
 -12.5%
H
0.5
0.6
|
L
 -5.8%
H
0.4
0.8
|
L
 -58.5%
H
0.4
1.5
|
L
 -92.1%
H
0.4
10.4
|
L
 -98.3%
H
0.4
29.9
|
L
 -99.2%
H
0.4
102.4
|
| Edgewise Therapeutics Inc |
|
4,834.0
|
44.5
|
L
 -0.3%
H
44.4
46.0
|
L
 -0.3%
H
42.6
48.5
|
L
 0.8%
H
40.6
48.5
|
L
 20.9%
H
36.0
48.5
|
L
 212.1%
H
14.3
48.5
|
L
 623.7%
H
5.1
48.5
|
L
 146.7%
H
5.1
48.5
|
L
H
5.1
48.5
|
| Evaxion Biotech A/S (ADR) |
|
29.5
|
3.3
|
L
 1.9%
H
3.2
3.3
|
L
 6.5%
H
3
3.3
|
L
 -1.2%
H
2.9
3.6
|
L
 7.2%
H
2.8
3.6
|
L
 5.8%
H
2.8
12.2
|
L
 -56.4%
H
0.8
13.6
|
L
 -96.0%
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
309.1
|
2.6
|
L
 2.0%
H
2.5
2.6
|
L
 10.3%
H
2.3
2.7
|
L
 10.7%
H
2.2
2.7
|
L
 23.4%
H
1.8
3.2
|
L
 168.8%
H
0.9
3.2
|
L
 17.8%
H
0.7
8.8
|
L
 -96.2%
H
0.7
70.3
|
L
 -18.9%
H
0.7
121.2
|
| 4D Molecular Therapeutics Inc |
|
877.3
|
15.9
|
L
 4.2%
H
15.1
16.2
|
L
 15.4%
H
13.2
16.2
|
L
 0.3%
H
12.9
16.3
|
L
 64.4%
H
9.4
16.9
|
L
 140.6%
H
6.5
16.9
|
L
 9.9%
H
2.2
36.3
|
L
 -54.6%
H
2.2
36.3
|
L
H
2.2
55.1
|
| Fennec Pharma Inc |
|
386.1
|
11.0
|
L
 0.9%
H
10.8
11.3
|
L
 2.7%
H
10.1
11.3
|
L
 -2.5%
H
10.1
12.8
|
L
 21.5%
H
9.1
13.3
|
L
 27.0%
H
5.7
13.3
|
L
 50.2%
H
4.0
13.3
|
L
 27.9%
H
3.8
13.3
|
L
 442.4%
H
1.6
15.0
|
| Foghorn Therapeutics Inc |
|
251.8
|
4.2
|
L
 2.2%
H
4.2
4.3
|
L
 -2.8%
H
4.1
4.4
|
L
 -40.0%
H
4.1
7.4
|
L
 2.2%
H
4.0
7.6
|
L
 -15.5%
H
3.3
7.6
|
L
 -27.9%
H
2.7
10.2
|
L
 -70.1%
H
2.7
24.3
|
L
H
2.7
28.3
|
| First Wave BioPharma Inc |
|
6.1
|
3.9
|
L
 14.4%
H
3.4
3.9
|
L
 31.0%
H
2.9
3.9
|
L
 9.0%
H
2.7
4.2
|
L
 -28.0%
H
2.6
5.7
|
L
 -24.6%
H
1.9
6.9
|
L
 -45.8%
H
0.4
14.5
|
L
 -100.0%
H
0.4
16359.9
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
417.5
|
4.1
|
L
 4.6%
H
4.1
4.2
|
L
 7.8%
H
3.6
4.2
|
L
 12.5%
H
3.6
4.7
|
L
 46.8%
H
2.7
5.6
|
L
 -13.8%
H
2.0
7.1
|
L
 131.3%
H
0.7
7.1
|
L
 10.1%
H
0.7
7.1
|
L
 59.2%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
85.1
|
2.0
|
L
 6.0%
H
1.8
2.0
|
L
 12.1%
H
1.7
2.0
|
L
 -2.5%
H
1.7
2.1
|
L
 3.7%
H
1.6
2.4
|
L
 23.4%
H
1.5
4.3
|
L
 -39.6%
H
0.9
5.3
|
L
 -73.8%
H
0.9
9.7
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
10.8
|
0.9
|
L
 -6.2%
H
0.9
1.0
|
L
 7.1%
H
0.8
1.0
|
L
 -11.7%
H
0.8
1
|
L
 -15.7%
H
0.7
1.2
|
L
 -51.1%
H
0.7
3.7
|
L
 -74.7%
H
0.7
5.5
|
L
H
0.7
9.3
|
L
H
0.7
9.3
|
| Geron Corp |
|
841.6
|
1.3
|
L
 0.8%
H
1.3
1.3
|
L
 -4.4%
H
1.3
1.4
|
L
 -13.8%
H
1.3
1.6
|
L
 4.0%
H
1.2
1.7
|
L
 -0.8%
H
1.0
2.0
|
L
 -39.6%
H
1.0
5.3
|
L
 -5.1%
H
1.0
5.3
|
L
 -41.8%
H
0.8
7.0
|
| Gilead Sciences |
|
189,304.0
|
152.7
|
L
 1.4%
H
148.7
153.3
|
L
 4.9%
H
142.9
153.3
|
L
 4.5%
H
142.9
153.3
|
L
 23.4%
H
123
153.3
|
L
 33.8%
H
108.5
157.3
|
L
 102.8%
H
62.1
157.3
|
L
 112.8%
H
57.2
157.3
|
L
 86.9%
H
56.6
157.3
|
| Greenwich LifeSciences Inc |
|
285.9
|
19.5
|
L
 4.7%
H
18.3
20.3
|
L
 21.4%
H
15.4
20.3
|
L
 16.9%
H
14.3
20.3
|
L
 -16.7%
H
12.5
24.6
|
L
 70.0%
H
7.8
34.1
|
L
 120.4%
H
7.6
34.1
|
L
 -54.4%
H
6.8
45.2
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,074.9
|
12.6
|
L
 2.8%
H
12.2
12.7
|
L
 -9.4%
H
12.0
13.9
|
L
 -11.9%
H
12.0
15
|
L
 -31.2%
H
12.0
25.2
|
L
 99.1%
H
6.2
25.8
|
L
 105.2%
H
2.4
25.8
|
L
 -49.0%
H
2.4
27.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
3.3
|
0.4
|
L
H
0.4
0.4
|
L
 -16.3%
H
0.4
0.5
|
L
 -44.6%
H
0.4
0.9
|
L
 -73.1%
H
0.4
1.4
|
L
 -97.8%
H
0.4
17.5
|
L
 -99.8%
H
0.4
276.8
|
L
 -100.0%
H
0.4
2103.8
|
L
 -100.0%
H
0.4
379518072.3
|
| GRI Bio Inc |
|
4.5
|
2.1
|
L
 5.7%
H
1.9
2.1
|
L
 8.5%
H
1.7
2.2
|
L
 24.2%
H
1.7
3.4
|
L
 9.0%
H
1.4
3.4
|
L
 -96.0%
H
1.4
64.1
|
L
 -100.0%
H
1.4
77102.5
|
L
 -100.0%
H
1.4
11097548.5
|
L
H
1.4
13462627.3
|
| Graphite Bio Inc |
|
240.5
|
4.1
|
L
 1.2%
H
4.1
4.2
|
L
 -7.6%
H
4
4.4
|
L
 -11.8%
H
4
6.0
|
L
 -32.9%
H
4
6.7
|
L
 -90.2%
H
4
50.4
|
L
 -96.4%
H
4
413
|
L
 -99.5%
H
4
847.7
|
L
H
4
1666
|
| Galapagos NV (ADR) |
|
1,989.4
|
30.2
|
L
 2.0%
H
29.6
30.3
|
L
 13.0%
H
26.6
30.3
|
L
 4.8%
H
26.6
30.3
|
L
 6.7%
H
25.7
30.9
|
L
 -11.6%
H
25.7
37.8
|
L
 -14.1%
H
22.4
42.5
|
L
 -44.1%
H
22.4
72.1
|
L
 -55.3%
H
22.4
274.0
|
| Genmab (ADR) |
|
21,656.9
|
35.2
|
L
 1.5%
H
34.4
35.3
|
L
 7.9%
H
32.3
35.3
|
L
 5.3%
H
32.2
35.3
|
L
 39.4%
H
24.9
35.3
|
L
 24.5%
H
23.6
35.4
|
L
 -3.5%
H
17.2
36.7
|
L
 -20.4%
H
17.2
47.5
|
L
 103.2%
H
12.1
49.1
|
| Halozyme Therapeutics Inc |
|
13,067.0
|
115.1
|
L
 3.3%
H
111.0
115.2
|
L
 6.7%
H
105.5
115.2
|
L
 6.4%
H
103.5
115.2
|
L
 68.0%
H
68.3
115.2
|
L
 48.0%
H
61.2
115.2
|
L
 188.5%
H
32.8
115.2
|
L
 179.6%
H
29.9
115.2
|
L
 826.2%
H
8.2
115.2
|
| HCW Biologics Inc |
|
3.3
|
1.8
|
L
 -5.2%
H
1.7
2.0
|
L
 -17.7%
H
1.7
2.2
|
L
 -17.0%
H
1.7
3.8
|
L
 -72.3%
H
1.7
7.2
|
L
 -92.9%
H
1.5
29.3
|
L
 -100.0%
H
1.5
24192
|
L
 -100.0%
H
1.5
67680
|
L
H
1.5
74640
|
| Hillstream BioPharma Inc |
|
28.8
|
2.5
|
L
 0.4%
H
2.3
2.5
|
L
 16.7%
H
1.9
2.5
|
L
 11.9%
H
1.9
2.5
|
L
 -26.9%
H
1.8
3.5
|
L
 -31.9%
H
1.8
6.9
|
L
 -56.3%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
57.0
|
0.3
|
L
 11.1%
H
0.3
0.3
|
L
 -6.3%
H
0.3
0.3
|
L
 -6.3%
H
0.3
0.4
|
L
 -28.6%
H
0.3
0.5
|
L
 -75.6%
H
0.3
1.6
|
L
 -72.2%
H
0.3
3.9
|
L
 -97.6%
H
0.3
12.9
|
L
 -98.5%
H
0.3
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
29.9
|
3.7
|
L
 2.5%
H
3.6
3.9
|
L
 6.9%
H
3.3
3.9
|
L
 7.6%
H
2.9
3.9
|
L
 -2.6%
H
2.7
4.4
|
L
 -80.4%
H
2.1
19.4
|
L
 -95.8%
H
2.1
97.5
|
L
 -96.4%
H
2.1
136.5
|
L
H
2.1
11431.9
|
| Humacyte Inc |
|
161.1
|
0.6
|
L
 -1.7%
H
0.6
0.6
|
L
 3.6%
H
0.5
0.6
|
L
 -9.4%
H
0.5
0.7
|
L
 -37.0%
H
0.5
0.9
|
L
 -68.8%
H
0.5
2.6
|
L
 -80.2%
H
0.5
10.0
|
L
 -95.8%
H
0.5
14.5
|
L
H
0.5
17.5
|
| Immucell Corp |
|
90.7
|
10.0
|
L
 -1.4%
H
9.8
10.1
|
L
 2.9%
H
9.5
10.2
|
L
 -0.7%
H
9.5
10.3
|
L
 5.3%
H
9.5
12.1
|
L
 67.6%
H
4.5
12.1
|
L
 91.4%
H
3.3
12.1
|
L
 2.4%
H
3.3
12.1
|
L
 23.0%
H
3.3
13.2
|
| InflaRx N.V. |
|
306.5
|
2.1
|
L
 -1.9%
H
2.0
2.2
|
L
 -1.9%
H
2.0
2.2
|
L
 -1.0%
H
2.0
2.5
|
L
 14.9%
H
1.6
2.6
|
L
 55.2%
H
0.8
3.0
|
L
 -33.1%
H
0.7
3.2
|
L
 -24.4%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
55.1
|
4.9
|
L
 0.8%
H
4.8
5.0
|
L
 -3%
H
4.6
5.3
|
L
 -12.0%
H
4.6
5.7
|
L
 -19.2%
H
4.6
6.3
|
L
 -41.2%
H
3.9
9.1
|
L
 -90.3%
H
3.9
59.3
|
L
 -97.1%
H
3.9
210
|
L
H
3.9
451.3
|
| Immunome Inc |
|
2,924.6
|
25.8
|
L
 2.7%
H
25.1
25.8
|
L
 4.9%
H
23.4
25.8
|
L
 -9.7%
H
23.4
29.7
|
L
 37.4%
H
19
30.1
|
L
 174.2%
H
9.4
30.1
|
L
 256.6%
H
5.2
31.0
|
L
 6.6%
H
2.1
31.0
|
L
H
2.1
63.8
|
| Imunon Inc |
|
8.5
|
1.5
|
L
 5.6%
H
1.4
1.6
|
L
 3.4%
H
1.3
1.6
|
L
 -7.9%
H
1.3
1.8
|
L
 -17.0%
H
1.3
2.2
|
L
 -69.7%
H
1.3
5.6
|
L
 -90.6%
H
1.3
54.8
|
L
 -99.3%
H
1.3
236.3
|
L
 -100.0%
H
1.3
4095
|
| Immunovant Inc |
|
7,702.3
|
37.3
|
L
 0.3%
H
36.8
38.2
|
L
 -1.0%
H
36.1
38.4
|
L
 -16.0%
H
36.1
44.5
|
L
 5.5%
H
35.9
45.4
|
L
 152.3%
H
14.6
45.4
|
L
 75.5%
H
12.7
45.6
|
L
 331.1%
H
3.1
45.6
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
11.2
|
1.1
|
L
 7.6%
H
1.1
1.2
|
L
 2.7%
H
1.0
1.2
|
L
 -10.9%
H
1.0
1.3
|
L
 -20.3%
H
0.9
1.5
|
L
 -43%
H
0.9
2.7
|
L
 -1.7%
H
0.1
4.2
|
L
 -83.0%
H
0.1
9.4
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
5,243.3
|
110.7
|
L
 -1.2%
H
109.1
117.1
|
L
 0.2%
H
99.1
117.1
|
L
 6.8%
H
94
131.0
|
L
 18.9%
H
77.5
131.0
|
L
 301.0%
H
26.2
155.3
|
L
 467.0%
H
10.8
155.3
|
L
 196.6%
H
7.7
155.3
|
L
H
7.7
155.3
|
| MiNK Therapeutics Inc |
|
61.8
|
12.1
|
L
 -1.1%
H
11.5
12.4
|
L
 1.2%
H
11.3
12.7
|
L
 -0.7%
H
10.8
12.7
|
L
 -0.3%
H
10.2
12.7
|
L
 -19.8%
H
8.5
17.0
|
L
 -7.6%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
59.9
|
2.2
|
L
 -5.7%
H
2.2
2.4
|
L
 -7.3%
H
2.0
2.4
|
L
 -6.9%
H
2.0
2.6
|
L
 49.0%
H
1.3
2.6
|
L
 13.7%
H
1.1
2.6
|
L
 -69.6%
H
1.1
14.7
|
L
 -88.4%
H
1.1
21.7
|
L
H
1.1
30.4
|
| Iovance Biotherapeutics Inc |
|
4,819.6
|
10.6
|
L
 4.4%
H
10.0
10.8
|
L
 14.9%
H
9.0
11.0
|
L
 28.4%
H
7.7
11.0
|
L
 172.1%
H
3.8
11.0
|
L
 419.0%
H
1.8
11.0
|
L
 111.1%
H
1.6
18.3
|
L
 -56.7%
H
1.6
28.0
|
L
 28.0%
H
1.6
54.2
|
| MindWalk Holdings Corp |
|
69.7
|
1.5
|
L
 0.7%
H
1.4
1.5
|
L
 11.3%
H
1.1
1.5
|
L
 5.0%
H
1.1
1.5
|
L
 -3.3%
H
1.1
1.7
|
L
 -14.5%
H
1.0
3.0
|
L
 -28.5%
H
0.3
3.3
|
L
 -77.6%
H
0.3
6.9
|
L
 7300%
H
0.3
33.3
|
| Century Therapeutics Inc |
|
342.2
|
1.9
|
L
 2.2%
H
1.9
1.9
|
L
 -5.5%
H
1.8
2.1
|
L
 -8.7%
H
1.8
2.3
|
L
 -17.5%
H
1.8
2.6
|
L
 293.8%
H
0.4
3.0
|
L
 -12.9%
H
0.3
5.5
|
L
 -90.9%
H
0.3
25.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,629.1
|
68.5
|
L
 0.0%
H
67.7
69.8
|
L
 -0.6%
H
66.7
72.1
|
L
 -14.2%
H
66.7
83.6
|
L
 -3.3%
H
66.7
83.6
|
L
 12.7%
H
40
99.5
|
L
 39.8%
H
25.6
99.5
|
L
 51.2%
H
11.6
99.5
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
283.0
|
1.0
|
L
 -5.9%
H
0.9
1.0
|
L
 7.9%
H
0.7
1.1
|
L
 -4%
H
0.7
1.1
|
L
 -1.0%
H
0.5
1.1
|
L
 -21.3%
H
0.5
3.1
|
L
 -42.2%
H
0.4
5.2
|
L
 -98.0%
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,669.6
|
32.4
|
L
 0.8%
H
31.8
32.8
|
L
 -0.1%
H
31.1
32.8
|
L
 -12.1%
H
31.1
38.0
|
L
 13.4%
H
28.2
38.0
|
L
 -0.6%
H
27.6
40.7
|
L
 -36.8%
H
23.2
77.0
|
L
 -9.8%
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
41.3
|
0.3
|
L
 -3.5%
H
0.3
0.3
|
L
 -15.2%
H
0.3
0.3
|
L
 -28.2%
H
0.3
0.4
|
L
 -24.3%
H
0.3
0.5
|
L
 -82.6%
H
0.3
3.5
|
L
 -85.8%
H
0.3
3.5
|
L
 -92.4%
H
0.3
5
|
L
 -90.4%
H
0.3
8.0
|
| Inventiva (ADR) |
|
862.3
|
3.7
|
L
H
3.5
3.7
|
L
 -5.9%
H
3.5
4.0
|
L
 -22.0%
H
3.5
5.1
|
L
 2.2%
H
3.4
5.1
|
L
 -35.4%
H
3.4
8.0
|
L
 -12.9%
H
1.5
8.0
|
L
 -73.8%
H
1.5
15.8
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
1,068.1
|
17.5
|
L
 2.7%
H
17.0
17.5
|
L
 0.9%
H
16.0
17.5
|
L
 0.5%
H
16.0
20.3
|
L
 22.9%
H
14.2
20.3
|
L
 -25.5%
H
12.1
35.3
|
L
 82.7%
H
5.7
71.7
|
L
 -32.1%
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
20.6
|
0.6
|
L
 3.3%
H
0.6
0.7
|
L
 -1.6%
H
0.6
0.7
|
L
 -13.9%
H
0.6
0.7
|
L
 37.8%
H
0.3
1.0
|
L
 -75.2%
H
0.3
2.7
|
L
 -17.3%
H
0.3
31.0
|
L
 -94.2%
H
0.3
31.0
|
L
H
0.3
31.0
|
| Kamada Ltd |
|
511.9
|
8.9
|
L
 1.5%
H
8.7
8.9
|
L
 6.7%
H
8
9.0
|
L
 7.7%
H
7.9
9.0
|
L
 21.3%
H
6.9
9.0
|
L
 28.4%
H
6.5
9.4
|
L
 68.0%
H
4.1
9.4
|
L
 68.3%
H
3.7
9.4
|
L
 87.9%
H
3.7
13.3
|
| Kodiak Sciences Inc |
|
2,124.3
|
33.8
|
L
 4.3%
H
32.5
34.5
|
L
 2.0%
H
31.5
34.5
|
L
 -11.8%
H
31.5
40.1
|
L
 -6.5%
H
31.5
46.9
|
L
 254.7%
H
9.8
47.8
|
L
 1598.5%
H
1.4
47.8
|
L
 -66.9%
H
1.4
132.0
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
10,385.6
|
350.9
|
L
 5.1%
H
334.3
353.8
|
L
 3.2%
H
331.8
353.8
|
L
 1.2%
H
331.8
373.3
|
L
 0.8%
H
297.0
382.5
|
L
 114.5%
H
158.1
382.5
|
L
 195.4%
H
94.0
382.5
|
L
 524.1%
H
38.9
382.5
|
L
H
8.0
382.5
|
| TuHURA Biosciences Inc |
|
135.7
|
2.1
|
L
 -2.3%
H
2.1
2.2
|
L
 3.9%
H
2.0
2.2
|
L
 6.5%
H
2.0
2.2
|
L
 -17.1%
H
2.0
2.8
|
L
 -18.4%
H
0.4
3.4
|
L
 -98.6%
H
0.2
160.5
|
L
 -99.9%
H
0.2
2677.5
|
L
 -100.0%
H
0.2
118886.3
|
| Kura Oncology Inc |
|
1,043.5
|
11.7
|
L
 1.1%
H
11.6
12.0
|
L
 1.5%
H
11.0
12.2
|
L
 -1.4%
H
11.0
13.9
|
L
 18.1%
H
8.8
13.9
|
L
 42.2%
H
7.4
13.9
|
L
 29.9%
H
5.4
24.2
|
L
 -42.2%
H
5.4
24.2
|
L
 63.8%
H
4
43
|
| Kymera Therapeutics Inc |
|
10,149.4
|
122.1
|
L
 3.7%
H
117.9
122.4
|
L
 6.5%
H
110.3
122.4
|
L
 1.9%
H
110.3
127.9
|
L
 35.0%
H
91.7
130.1
|
L
 148.4%
H
47.9
130.1
|
L
 602.7%
H
9.6
130.1
|
L
 104.9%
H
9.6
130.1
|
L
H
9.6
130.1
|
| Kazia Therapeutics Ltd (ADR) |
|
169.8
|
10.9
|
L
 2.5%
H
10.7
11.3
|
L
 -2.2%
H
10.2
11.3
|
L
 -18.5%
H
10.2
17.2
|
L
 -21.2%
H
10.2
17.2
|
L
 40.7%
H
4.9
17.4
|
L
 -78.2%
H
2.9
79
|
L
 -98.0%
H
2.9
614
|
L
 -97.2%
H
2.9
792.5
|
| Longeveron Inc (Class A) |
|
8.7
|
2.7
|
L
 11.0%
H
2.3
2.8
|
L
 -60.7%
H
2.3
7.2
|
L
 -67.8%
H
2.3
8.7
|
L
 -66.8%
H
2.3
8.9
|
L
 -65.4%
H
2.3
12.3
|
L
 -98.8%
H
2.3
429.8
|
L
 -99.2%
H
2.3
4500
|
L
H
2.3
4500
|
| Lixte biotech Holdings Inc |
|
69.8
|
3.8
|
L
 3.8%
H
3.7
4.0
|
L
 16.8%
H
3.2
4.0
|
L
 -11.2%
H
3.2
4.6
|
L
 -49.8%
H
3.1
8.4
|
L
 -29.9%
H
2.4
8.4
|
L
 113.4%
H
0.6
8.4
|
L
 -80.9%
H
0.6
49.5
|
L
 -69.7%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
402.0
|
3.7
|
L
 9.7%
H
3.4
3.9
|
L
 44.6%
H
2.1
4.0
|
L
 162.7%
H
1.5
4.0
|
L
 404.1%
H
0.6
4.0
|
L
 1186.2%
H
0.3
4.0
|
L
 176.3%
H
0.2
5
|
L
 -89.1%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
396.8
|
3.8
|
L
 -0.3%
H
3.8
4.0
|
L
 1.1%
H
3.7
4.1
|
L
 -8.6%
H
3.7
4.2
|
L
 5.0%
H
2.9
4.5
|
L
 -9.1%
H
2.7
6.4
|
L
 -6.6%
H
1.6
13.7
|
L
 -66.2%
H
1.5
13.7
|
L
 -90.2%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
273.2
|
11.2
|
L
 2.0%
H
10.9
11.2
|
L
 -1.6%
H
10.5
11.3
|
L
 -28.2%
H
10.5
15.7
|
L
 -12.5%
H
10.5
17.2
|
L
 -14.8%
H
10.5
45
|
L
 -62.3%
H
7.7
65.1
|
L
 -94.9%
H
7.7
309.9
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
92.7
|
1.4
|
L
 2.2%
H
1.3
1.4
|
L
 -4.8%
H
1.3
1.5
|
L
 -8%
H
1.3
1.6
|
L
 -25.8%
H
1.3
2.0
|
L
 -56.7%
H
1.3
3.7
|
L
H
0.8
4.7
|
L
 -81.0%
H
0.8
9.6
|
L
 -99.2%
H
0.8
234.9
|
| Seres Therapeutics Inc |
|
40.4
|
4.0
|
L
 -1.2%
H
3.9
4.2
|
L
 -15.0%
H
3.9
4.9
|
L
 -11.8%
H
3.9
6.0
|
L
 -39.2%
H
3.9
8.3
|
L
 -77.0%
H
3.9
30.0
|
L
 47.8%
H
0.4
30.0
|
L
 -41.8%
H
0.4
30.0
|
L
 -72.0%
H
0.4
38.5
|
| Magenta Therapeutics Inc |
|
-
|
98.4
|
L
 2.0%
H
96.6
100.5
|
L
 -8.7%
H
94.6
108.3
|
L
 -11.5%
H
94.6
113.9
|
L
 19.2%
H
83.9
117.9
|
L
 167.6%
H
32.2
117.9
|
L
 399.5%
H
16.6
117.9
|
L
 -16.1%
H
5.1
135.8
|
L
H
5.1
336
|
| MeiraGTx Holdings PLC |
|
1,186.1
|
12.4
|
L
 -5.6%
H
12.2
13.2
|
L
 -4.1%
H
12.2
13.5
|
L
 -13.9%
H
12.2
15.3
|
L
 9.1%
H
11.2
15.4
|
L
 63.4%
H
6.6
15.4
|
L
 140.3%
H
3.5
15.4
|
L
 -6.3%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,599.2
|
29.4
|
L
 3.9%
H
28.4
29.6
|
L
 1.6%
H
27.3
29.6
|
L
 14.6%
H
25.0
32.0
|
L
 19.4%
H
24.5
32.0
|
L
 -25.1%
H
22.3
47.7
|
L
 174.3%
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
648.6
|
96.6
|
L
 1.0%
H
94
97.4
|
L
 -10.8%
H
94
106.9
|
L
 -10.3%
H
94
121.0
|
L
 43.2%
H
66.8
124.8
|
L
 52.7%
H
50.1
124.8
|
L
 3047.6%
H
1.4
124.8
|
L
 275.3%
H
1.4
124.8
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
20.3
|
1.2
|
L
 1.7%
H
1.2
1.2
|
L
 4.3%
H
1.1
1.2
|
L
 -12.2%
H
1.1
1.6
|
L
 -8.3%
H
1.1
1.7
|
L
 28.4%
H
0.8
2.5
|
L
 -76.2%
H
0.8
6.2
|
L
 -93.0%
H
0.7
19
|
L
 -98.2%
H
0.7
135.5
|
| Moderna |
|
72,884.5
|
182.6
|
L
 5.6%
H
168.3
187.2
|
L
 24.5%
H
141.2
187.2
|
L
 25.8%
H
130
187.2
|
L
 185.4%
H
52.7
187.2
|
L
 623.3%
H
22.3
187.2
|
L
 82.1%
H
22.3
187.2
|
L
 -57.9%
H
22.3
458.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
1,111.5
|
7.5
|
L
 4.0%
H
7.0
7.5
|
L
 11.7%
H
6.6
7.5
|
L
 -13.7%
H
6.5
9.4
|
L
 43.5%
H
5.1
9.4
|
L
 176.3%
H
2.5
9.4
|
L
 -25.7%
H
1.7
11.6
|
L
 -84.0%
H
1.7
50.2
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
128.0
|
1.2
|
L
 1.6%
H
1.2
1.3
|
L
 5.1%
H
1.2
1.3
|
L
 -10.1%
H
1.1
1.4
|
L
 2.5%
H
1.0
1.5
|
L
 -18.4%
H
0.6
1.9
|
L
 -61.3%
H
0.6
5.5
|
L
 -91.3%
H
0.6
14.8
|
L
H
0.6
17.4
|
| Mainz Biomed N.V. |
|
111.0
|
1.3
|
L
 1.5%
H
1.3
1.4
|
L
H
1.3
1.4
|
L
 1.5%
H
1.3
1.7
|
L
 -25%
H
1.0
1.9
|
L
 -18.0%
H
0.3
4.9
|
L
 -99.0%
H
0.3
135.7
|
L
H
0.3
1200
|
L
H
0.3
1200
|
| Mesoblast Ltd (ADR) |
|
2,067.3
|
15.9
|
L
 2.8%
H
15.5
16.0
|
L
 6.0%
H
14.2
16.0
|
L
 -6.4%
H
14.2
18.3
|
L
 10.8%
H
13.1
19.4
|
L
 -6.4%
H
13.1
21.5
|
L
 1163.5%
H
1.0
22
|
L
 165.8%
H
1.0
22
|
L
 257.8%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
163.2
|
4.3
|
L
 6.8%
H
4.3
4.3
|
L
 6.0%
H
3.8
4.7
|
L
 -3.2%
H
3.8
4.7
|
L
 11.5%
H
3.7
4.7
|
L
 13%
H
3.5
5.4
|
L
 -3.6%
H
3.3
12.7
|
L
 -78.1%
H
3.3
32.0
|
L
 -82.9%
H
3.3
32.0
|
| Mereo Biopharma Grp PLC (ADR) |
|
51.1
|
0.3
|
L
 10.3%
H
0.3
0.3
|
L
 14.3%
H
0.3
0.3
|
L
 10.3%
H
0.2
0.3
|
L
 3.2%
H
0.2
0.4
|
L
 -81.6%
H
0.2
2.4
|
L
 -75.9%
H
0.2
5.0
|
L
 -87.4%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
127.3
|
1
|
L
 4.2%
H
1.0
1.0
|
L
 9.9%
H
0.9
1.0
|
L
 4.2%
H
0.9
1.1
|
L
 -56.1%
H
0.8
2.4
|
L
 47.1%
H
0.7
4.3
|
L
 -71.1%
H
0.6
4.3
|
L
 -85.6%
H
0.6
7.1
|
L
H
0.6
25.9
|
| Neurocrine Biosciences Inc |
|
14,459.6
|
142.3
|
L
 -1.2%
H
141.8
144.3
|
L
 -9.5%
H
141.8
156.7
|
L
 -6.8%
H
141.8
160.4
|
L
 -10.1%
H
141.8
186.1
|
L
 -2.1%
H
122.1
186.1
|
L
 25.8%
H
84.2
186.1
|
L
 48.9%
H
71.9
186.1
|
L
 162.4%
H
37.3
186.1
|
| Nkarta Inc |
|
211.3
|
3.0
|
L
 2.4%
H
2.9
3.0
|
L
 1.0%
H
2.7
3.1
|
L
 10.9%
H
2.5
3.3
|
L
 3.2%
H
2.0
3.7
|
L
 47.5%
H
1.7
3.7
|
L
 71.5%
H
1.3
16.2
|
L
 -90.4%
H
1.3
31.5
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
33.6
|
L
 3.2%
H
32.8
34.5
|
L
 -4.6%
H
31.2
35.6
|
L
 -13.0%
H
31.2
42.0
|
L
 6.6%
H
29.7
43.7
|
L
 95.4%
H
15.9
43.7
|
L
 140.3%
H
12.7
43.7
|
L
 -77.7%
H
7.5
160.3
|
L
 -87.7%
H
7.5
399.4
|
| MetaVia Inc |
|
11.1
|
1.7
|
L
 0.6%
H
1.6
1.7
|
L
 3.7%
H
1.5
1.7
|
L
 15.1%
H
1.4
1.9
|
L
 5%
H
1.4
2.6
|
L
 -85.3%
H
1.0
14.9
|
L
 -96.2%
H
1.0
74.3
|
L
 -100.0%
H
1.0
10861.0
|
L
 -100.0%
H
1.0
1424940
|
| Nurix Therapeutics Inc |
|
2,664.1
|
25.7
|
L
 1.0%
H
25.2
26.0
|
L
 0.6%
H
24.3
26.4
|
L
 -3.9%
H
24.3
27.5
|
L
 46.3%
H
17.8
28.2
|
L
 204.2%
H
8.2
28.2
|
L
 184.0%
H
4.2
29.6
|
L
 -26.0%
H
4.2
36.2
|
L
H
4.2
52.4
|
| Intellia Therapeutics Inc |
|
1,778.2
|
12.7
|
L
 3.9%
H
12.1
13.0
|
L
 6.9%
H
11.2
13.0
|
L
 -1.2%
H
11.2
13.7
|
L
 -19.0%
H
10.2
18.5
|
L
 -18.6%
H
8.0
28.3
|
L
 -62.2%
H
5.9
34.9
|
L
 -91.4%
H
5.9
155.6
|
L
 -32.1%
H
5.9
202.7
|
| Natera Inc |
|
56,346.0
|
390.9
|
L
 5.5%
H
365.2
391.9
|
L
 14.4%
H
338.8
391.9
|
L
 17.7%
H
316
391.9
|
L
 68.9%
H
219.5
391.9
|
L
 115.8%
H
157.4
391.9
|
L
 726.6%
H
36.9
391.9
|
L
 216.0%
H
26.1
391.9
|
L
 3706.2%
H
7.4
391.9
|
| Novavax Inc |
|
1,786.4
|
10.8
|
L
 4.0%
H
10.2
11.1
|
L
 12.9%
H
9.2
11.1
|
L
 21.1%
H
8.3
11.1
|
L
 18.6%
H
7.2
11.1
|
L
 24.3%
H
6.2
12.0
|
L
 59.0%
H
3.5
23.9
|
L
 -95.3%
H
3.5
260.7
|
L
 -72.1%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
5.5
|
1.3
|
L
 0.8%
H
1.3
1.4
|
L
 0.8%
H
1.3
1.4
|
L
 -12.5%
H
1.3
1.9
|
L
 -30.4%
H
1.2
2.0
|
L
 -64.0%
H
1.2
7.2
|
L
 -100.0%
H
1.2
810296.8
|
L
 -100.0%
H
1.2
3319720
|
L
H
1.2
32000000
|
| Insight Molecular Diagnostics Inc |
|
135.5
|
4.1
|
L
 3.2%
H
4.0
4.3
|
L
 3.0%
H
3.5
4.3
|
L
 -4.6%
H
3.5
4.5
|
L
 -23.9%
H
3.5
6.1
|
L
 21.4%
H
2.4
8.5
|
L
 28.6%
H
1.9
8.5
|
L
 -94.7%
H
1.9
81.3
|
L
 -95.5%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
70.8
|
1.4
|
L
 1.5%
H
1.3
1.4
|
L
 -3.6%
H
1.3
1.4
|
L
 -12.3%
H
1.3
1.7
|
L
 -15.1%
H
1.3
1.9
|
L
 -31.8%
H
1.3
3.2
|
L
 -30.4%
H
0.8
3.4
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
90.5
|
0.7
|
L
 -7.8%
H
0.7
0.8
|
L
 -12.4%
H
0.7
0.8
|
L
 -15.5%
H
0.7
0.9
|
L
 -26.0%
H
0.7
1.1
|
L
 -47.8%
H
0.7
1.5
|
L
 -67.6%
H
0.3
2.3
|
L
 -66.7%
H
0.3
3.4
|
L
 -74.3%
H
0.3
8.5
|
| Traws Pharma Inc |
|
7.7
|
0.5
|
L
H
0.5
0.5
|
L
 -3.9%
H
0.5
0.6
|
L
 -5.7%
H
0.5
0.6
|
L
 -41.2%
H
0.4
0.9
|
L
 -75.4%
H
0.4
3.3
|
L
 -97.5%
H
0.4
27.5
|
L
 -99.6%
H
0.4
169.3
|
L
 -100.0%
H
0.4
21825
|
| VivoSim Labs Inc |
|
3.2
|
0.2
|
L
 -4%
H
0.2
0.3
|
L
 -14.3%
H
0.2
0.3
|
L
 -17.2%
H
0.2
0.3
|
L
 -78.2%
H
0.2
1.6
|
L
 -94.2%
H
0.2
4.1
|
L
 -98.6%
H
0.2
24.6
|
L
 -99.7%
H
0.2
88.9
|
L
 -100.0%
H
0.2
993.6
|
| Passage Bio Inc |
|
15.9
|
5.0
|
L
 2.5%
H
4.7
5.0
|
L
 1.9%
H
4.7
5.0
|
L
 11.5%
H
4.3
5.4
|
L
 -11.5%
H
3.3
6.3
|
L
 -31.0%
H
3.3
20
|
L
 -63.7%
H
3.3
35.8
|
L
 -97.8%
H
3.3
227.4
|
L
H
3.3
764.6
|
| Vaxcyte Inc |
|
8,782.5
|
59.0
|
L
 0.2%
H
58.8
60.0
|
L
 -0.9%
H
57.0
61.5
|
L
 -5.8%
H
57.0
63.9
|
L
 14.7%
H
50.8
64.0
|
L
 85.9%
H
31.5
65
|
L
 13.1%
H
27.7
121.1
|
L
 133.6%
H
16.8
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
206.4
|
3.0
|
L
 4.9%
H
2.8
3.0
|
L
 0.3%
H
2.8
3.0
|
L
 -5.1%
H
2.8
3.6
|
L
 66.5%
H
1.6
3.6
|
L
 58.5%
H
1.3
7.8
|
L
 -45.8%
H
0.9
19.3
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
2,824.9
|
7.9
|
L
 2.5%
H
7.5
8.0
|
L
 15.2%
H
6.8
8.0
|
L
 9.6%
H
6.5
8.0
|
L
 63.7%
H
4.8
8.0
|
L
 110.4%
H
3.0
8.0
|
L
 463.6%
H
0.7
8.0
|
L
 45.3%
H
0.7
8.0
|
L
 -71.9%
H
0.7
32.9
|
| Phio Pharma Corp |
|
11.6
|
1
|
L
 -1.0%
H
1.0
1.1
|
L
 -2.9%
H
1.0
1.1
|
L
 -15.3%
H
1.0
1.2
|
L
 -2.9%
H
0.8
1.2
|
L
 -51.7%
H
0.8
4.2
|
L
 -92.1%
H
0.6
29.1
|
L
 -99.6%
H
0.6
261.4
|
L
 -100.0%
H
0.6
174042
|
| Pharvaris NV |
|
2,471.2
|
35.2
|
L
 -2.3%
H
34.9
36.3
|
L
 -9.4%
H
34.9
40
|
L
 -3.0%
H
33.8
43.3
|
L
 7.3%
H
31.5
43.3
|
L
 38.8%
H
20.7
43.3
|
L
 78.0%
H
11.5
43.3
|
L
 95.1%
H
1.8
43.3
|
L
H
1.8
43.3
|
| Pliant Therapeutics Inc |
|
70.6
|
1.1
|
L
 2.7%
H
1.1
1.2
|
L
 -0.9%
H
1.1
1.2
|
L
 -1.7%
H
1.1
1.2
|
L
 -1.7%
H
1.0
1.2
|
L
 -20.3%
H
1.0
2.0
|
L
 -92.8%
H
1.0
19.6
|
L
 -93.6%
H
1.0
36.6
|
L
H
1.0
43.9
|
| Pluri Inc |
|
13.6
|
1.1
|
L
 2.8%
H
1
1.1
|
L
 -11.3%
H
1
1.3
|
L
 -35.7%
H
1
1.7
|
L
 -45.5%
H
1
2.4
|
L
 -76.1%
H
1
4.9
|
L
 -77.1%
H
0.7
8.5
|
L
 -95.4%
H
0.7
25.5
|
L
 -99.2%
H
0.7
169.6
|
| ProMIS Neurosciences Inc |
|
121.8
|
13.6
|
L
 -0.4%
H
13.5
14.2
|
L
 2.4%
H
12.4
14.2
|
L
 -6.4%
H
12.3
15.5
|
L
 28.8%
H
10.2
17.3
|
L
 22.9%
H
6.3
27.4
|
L
 -72.8%
H
6.3
77.5
|
L
 -94.0%
H
6.3
245
|
L
 -91.0%
H
6.3
1050
|
| PMV Pharmaceuticals Inc |
|
80.7
|
1.5
|
L
 2.0%
H
1.5
1.5
|
L
 3.4%
H
1.4
1.5
|
L
 13.5%
H
1.1
1.5
|
L
 33.6%
H
1.0
1.5
|
L
 15.3%
H
1.0
1.9
|
L
 -77.5%
H
0.8
6.9
|
L
 -94.5%
H
0.8
30.5
|
L
H
0.8
63.2
|
| Prelude Therapeutics Inc |
|
387.0
|
4.9
|
L
 3.2%
H
4.6
4.9
|
L
 5.7%
H
4.4
4.9
|
L
 -26.9%
H
4.4
6.8
|
L
 12.3%
H
3.8
6.8
|
L
 394.9%
H
1.0
6.8
|
L
 73.8%
H
0.6
6.8
|
L
 -85.9%
H
0.6
37.0
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
642.1
|
3.5
|
L
 11.0%
H
3.2
3.6
|
L
 11.3%
H
2.9
3.6
|
L
 4.4%
H
2.9
3.9
|
L
 9.6%
H
2.7
4.8
|
L
 -27.6%
H
2.7
6.9
|
L
 -68.4%
H
1.1
11.4
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
382.3
|
1.8
|
L
 2.8%
H
1.8
1.9
|
L
 1.1%
H
1.7
2.0
|
L
 13.7%
H
1.6
2.1
|
L
H
1.3
2.2
|
L
 -31.7%
H
1.3
3.5
|
L
 -57.9%
H
0.5
7.1
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
461.5
|
9.0
|
L
 5.6%
H
8.7
9.1
|
L
 1.5%
H
8.2
9.1
|
L
 -4.9%
H
8.2
9.9
|
L
 0.7%
H
8
10.2
|
L
 11.4%
H
7.7
11.8
|
L
 -82.4%
H
4.3
55.9
|
L
 -88.0%
H
4.3
79.8
|
L
 -85.5%
H
4.3
79.8
|
| Quince Therapeutics Inc |
|
31.9
|
31.4
|
L
 1.1%
H
30.5
33.0
|
L
 9.7%
H
25.8
33.0
|
L
 -7.6%
H
25.8
35.3
|
L
 3235.1%
H
0.9
35.4
|
L
 95.9%
H
0.8
45.5
|
L
 167.9%
H
0.8
45.5
|
L
 -96.4%
H
0.8
985
|
L
H
0.8
1219.8
|
| uniQure NV |
|
3,140.9
|
45.3
|
L
 2.2%
H
44.5
45.8
|
L
 0.8%
H
41.7
45.8
|
L
 -6.4%
H
41.7
51.7
|
L
 -2.2%
H
35.3
51.7
|
L
 226.5%
H
8.7
71.5
|
L
 538.6%
H
3.7
71.5
|
L
 18.5%
H
3.7
71.5
|
L
 484.3%
H
3.7
82.5
|
| Rani Therapeutics Holdings Inc |
|
90.0
|
0.8
|
L
 -1.3%
H
0.8
0.8
|
L
 -7.1%
H
0.8
0.9
|
L
 -11.4%
H
0.8
0.9
|
L
H
0.6
0.9
|
L
 50%
H
0.4
3.9
|
L
 -73.6%
H
0.4
8.8
|
L
 -96.0%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
367.7
|
3.4
|
L
 2.5%
H
3.3
3.4
|
L
 -2.3%
H
3.2
3.8
|
L
 -4.6%
H
3.2
4.0
|
L
H
3.0
4.3
|
L
 9.1%
H
2.5
5.5
|
L
 -83.9%
H
2.2
32.5
|
L
 -89.7%
H
2.2
36.9
|
L
 -90.5%
H
2.2
67.5
|
| Replimune Grp Inc |
|
1,269.1
|
13.5
|
L
 4.7%
H
12.8
13.6
|
L
 2.8%
H
12.5
13.6
|
L
 -8.8%
H
12.4
16.3
|
L
 32.2%
H
4.8
16.3
|
L
 318.3%
H
1.5
16.3
|
L
 -19.8%
H
1.5
17.1
|
L
 -58.3%
H
1.5
35.9
|
L
H
1.5
54.9
|
| Revelation Biosciences Inc |
|
3.9
|
1.0
|
L
H
1.0
1.0
|
L
 2.1%
H
0.9
1.0
|
L
 -10.1%
H
0.9
1.1
|
L
H
0.9
1.2
|
L
 -84.1%
H
0.9
6.8
|
L
 -100.0%
H
0.9
4849.9
|
L
 -100.0%
H
0.9
2276064
|
L
H
0.9
2276064
|
| Relay Therapeutics Inc |
|
4,240.4
|
19.4
|
L
 6.4%
H
18.2
19.5
|
L
 1.5%
H
18.1
19.7
|
L
 -0.5%
H
18.0
20.8
|
L
 21.9%
H
16.1
21.3
|
L
 315.2%
H
4.3
21.3
|
L
 125.3%
H
1.8
21.3
|
L
 -47.6%
H
1.8
38.2
|
L
H
1.8
64.4
|
| Rallybio Corp |
|
89.9
|
16.9
|
L
 -0.1%
H
16.7
17.1
|
L
 2.5%
H
16.5
17.2
|
L
 0.5%
H
16.5
17.3
|
L
 6.0%
H
15.6
17.4
|
L
 259.2%
H
3.7
17.6
|
L
 -55.8%
H
1.8
40.2
|
L
 -80.8%
H
1.8
168
|
L
H
1.8
206.2
|
| TransCode Therapeutics Inc |
|
30.0
|
1.8
|
L
 0.6%
H
1.7
1.9
|
L
 7.3%
H
1.6
2
|
L
 -38.3%
H
1.6
2.9
|
L
 -62.3%
H
1.6
10.7
|
L
 -84.9%
H
1.6
21.0
|
L
 -100.0%
H
1.6
118272
|
L
 -100.0%
H
1.6
3901941.1
|
L
H
1.6
5174400
|
| Recursion Pharma Inc (Class A) |
|
2,171.9
|
4.1
|
L
 2.0%
H
3.9
4.2
|
L
 18.8%
H
3.2
4.2
|
L
 15.7%
H
3.1
4.2
|
L
 25.4%
H
2.8
4.2
|
L
 -17.5%
H
2.8
7.2
|
L
 -49.2%
H
2.8
15.7
|
L
 -84.1%
H
2.8
26
|
L
H
2.8
42.8
|
| SAB Biotherapeutics Inc |
|
318.5
|
3.5
|
L
 3.2%
H
3.4
3.6
|
L
 1.2%
H
3.3
3.6
|
L
 -7.4%
H
3.3
4.0
|
L
 -12.5%
H
3.3
4.1
|
L
 41.7%
H
1.9
5.2
|
L
 525%
H
0.4
6.6
|
L
 -65.1%
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
996.9
|
3.3
|
L
 7.4%
H
3.1
3.4
|
L
 4.1%
H
2.9
3.4
|
L
 -14.8%
H
2.9
4.2
|
L
 5.7%
H
2.9
4.2
|
L
 7.8%
H
2.6
6.6
|
L
 -15.9%
H
1.3
12
|
L
 -85.9%
H
1.3
23.7
|
L
H
1.3
44.6
|
| Filana Therapeutics Inc |
|
49.8
|
1.0
|
L
 39.2%
H
0.9
1.3
|
L
 43.1%
H
0.7
1.3
|
L
 7.3%
H
0.7
1.3
|
L
 -15.6%
H
0.7
1.4
|
L
 -54.8%
H
0.7
5.0
|
L
 -94.2%
H
0.7
42.2
|
L
 -98.1%
H
0.7
100
|
L
 -94.7%
H
0.7
146.2
|
| Seer Inc (Class A) |
|
103.0
|
1.9
|
L
H
1.9
1.9
|
L
 -2.6%
H
1.8
1.9
|
L
 -8.4%
H
1.8
2.1
|
L
 6.9%
H
1.6
2.3
|
L
 -16.6%
H
1.6
2.4
|
L
 -18.1%
H
1.5
2.6
|
L
 -94.9%
H
1.5
38.9
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,251.2
|
8.1
|
L
 1.8%
H
8.0
8.3
|
L
 0.5%
H
7.7
8.3
|
L
 -19.5%
H
7.7
10.9
|
L
 -16.1%
H
7.3
11
|
L
 -14.4%
H
5.6
11
|
L
 -21.2%
H
5.6
15.6
|
L
 -21.2%
H
5.6
15.6
|
L
 -21.2%
H
5.6
15.6
|
| Solid Biosciences Inc |
|
956.4
|
8.9
|
L
 4.5%
H
8.6
9.0
|
L
 2.1%
H
8.2
9.0
|
L
 -4.1%
H
8.2
10.5
|
L
 7.1%
H
7.7
11.5
|
L
 74.2%
H
3.8
11.5
|
L
 225.5%
H
1.8
15.1
|
L
 -81.4%
H
1.8
50.4
|
L
H
1.8
822.6
|
| Decoy Therapeutics Inc |
|
2.0
|
3.1
|
L
 21.1%
H
3
7.6
|
L
 14.4%
H
2.2
7.6
|
L
 -3.1%
H
2.2
7.6
|
L
 -48.9%
H
2.2
13.5
|
L
 -94.0%
H
2.2
55.9
|
L
 -99.7%
H
2.2
1368
|
L
 -100.0%
H
2.2
43200
|
L
 -100.0%
H
2.2
10791000
|
| Summit Therapeutics Inc |
|
13,657.5
|
17.1
|
L
 1.3%
H
16.8
17.5
|
L
 -7.1%
H
16.6
18.5
|
L
 30.1%
H
12.2
18.8
|
L
 24.5%
H
12.1
18.8
|
L
 -9.4%
H
12.1
29.2
|
L
 835.5%
H
1.6
36.9
|
L
 164.2%
H
0.7
36.9
|
L
 119.5%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,623.4
|
18.2
|
L
 0.6%
H
18.0
18.6
|
L
 -0.9%
H
17.3
18.6
|
L
 -7.5%
H
17.3
21
|
L
 -4.3%
H
17.2
25.2
|
L
 23%
H
13.0
25.6
|
L
 11.8%
H
8.6
25.6
|
L
 -2.1%
H
8.6
29.9
|
L
 29.5%
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
863.1
|
33.4
|
L
 0.3%
H
32.2
33.7
|
L
 -14.6%
H
32.1
39.9
|
L
 4.4%
H
30.3
42.1
|
L
 87.4%
H
17.5
42.1
|
L
 271.1%
H
7.5
42.1
|
L
 103.7%
H
5
42.1
|
L
 -85.1%
H
5
238.4
|
L
H
5
530
|
| Senti Biosciences Inc |
|
10.0
|
0.3
|
L
 3.2%
H
0.3
0.3
|
L
 6.7%
H
0.3
0.3
|
L
 -18.0%
H
0.3
0.4
|
L
 -65.6%
H
0.3
1.2
|
L
 -76.3%
H
0.3
2.9
|
L
 -93.9%
H
0.3
16.9
|
L
 -67.7%
H
0.3
87.7
|
L
H
0.3
87.7
|
| Spruce Biosciences Inc |
|
143.7
|
50.0
|
L
 -6.9%
H
49.2
55.0
|
L
 -12.1%
H
49.2
57.1
|
L
 -3.1%
H
49.2
64.5
|
L
 -4.5%
H
40.3
64.5
|
L
 496.5%
H
7.3
240
|
L
 -72.7%
H
4.3
446.3
|
L
 -89.8%
H
4.3
489.8
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
79.2
|
1.4
|
L
 19.3%
H
1.3
1.4
|
L
 19.3%
H
1.1
1.4
|
L
 11.5%
H
1.1
1.4
|
L
 -40.4%
H
1.1
2.4
|
L
 -32%
H
1.1
3.1
|
L
 11.5%
H
0.5
3.2
|
L
 -92.9%
H
0.5
19.9
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
6,234.2
|
51.2
|
L
 6.3%
H
48.1
51.7
|
L
 -1.3%
H
45.9
51.7
|
L
 -9.4%
H
45.9
61.8
|
L
 8.2%
H
45.7
61.8
|
L
 66.0%
H
27.1
61.8
|
L
 711.3%
H
6.0
61.8
|
L
 49.5%
H
4.3
61.8
|
L
H
4.3
70
|
| Surrozen Inc |
|
206.9
|
17.6
|
L
 6.5%
H
16.6
17.6
|
L
 -1.4%
H
16.4
18.3
|
L
 -26.6%
H
16.4
25.0
|
L
 -24.3%
H
16.4
27.3
|
L
 43.3%
H
11.4
35
|
L
 3726.1%
H
0.3
35
|
L
 61.6%
H
0.3
35
|
L
H
0.3
35
|
| Stoke Therapeutics Inc |
|
1,884.2
|
29.2
|
L
 4.1%
H
28.2
29.4
|
L
 -1.4%
H
27.7
29.6
|
L
 -9.6%
H
27.7
33.9
|
L
 -5.8%
H
27.2
33.9
|
L
 27.5%
H
20.3
40.2
|
L
 603.6%
H
3.4
40.2
|
L
 16.8%
H
3.4
40.2
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
652.4
|
6.5
|
L
 6.4%
H
6.1
6.5
|
L
 4.8%
H
5.8
6.5
|
L
 -13.7%
H
5.8
8.2
|
L
 31.3%
H
5
8.2
|
L
 185.1%
H
1.7
8.3
|
L
 324.8%
H
0.7
11.8
|
L
 -66.5%
H
0.7
21.4
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
3.7
|
1.0
|
L
 3.0%
H
1.0
1.1
|
L
 15.6%
H
0.8
1.1
|
L
 -8.0%
H
0.8
1.2
|
L
 -36.6%
H
0.8
1.9
|
L
 -80.9%
H
0.8
8.6
|
L
 -99.5%
H
0.8
367.2
|
L
H
0.8
2076
|
L
H
0.8
2076
|
| Alaunos Therapeutics Inc |
|
3.2
|
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 -14.8%
H
1.0
1.7
|
L
 -27.8%
H
1.0
1.8
|
L
 -40.9%
H
1.0
2.5
|
L
 -47.5%
H
1.0
4.6
|
L
 876.9%
H
0.0
6.2
|
L
 -32.8%
H
0.0
6.2
|
L
 -78.2%
H
0.0
7.9
|
| Tscan Therapeutics Inc |
|
24.4
|
0.4
|
L
 9.1%
H
0.3
0.4
|
L
 16.1%
H
0.3
0.4
|
L
 -53.9%
H
0.3
0.8
|
L
 -60.9%
H
0.3
1.3
|
L
 -79.9%
H
0.3
2.6
|
L
 -86.4%
H
0.3
9.7
|
L
 -94.4%
H
0.3
9.7
|
L
H
0.3
14.7
|
| Bio-Techne |
|
11,377.2
|
72.6
|
L
 0.1%
H
72.5
72.7
|
L
 0.4%
H
72.2
72.7
|
L
 0.4%
H
72.1
72.7
|
L
 25.2%
H
55.5
72.7
|
L
 36.5%
H
43.2
72.7
|
L
 3.8%
H
43.2
85.6
|
L
 -45.3%
H
43.2
136.0
|
L
 170.0%
H
23.9
136.0
|
| Instil Bio Inc |
|
48.4
|
7.1
|
L
 0.9%
H
7
7.2
|
L
 -4.3%
H
6.9
7.5
|
L
 -5.9%
H
6.9
7.9
|
L
 -4.9%
H
6.9
8.1
|
L
 -64.2%
H
5.7
22.0
|
L
 1597.6%
H
0.3
92
|
L
 -66.0%
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
4,304.6
|
25.5
|
L
 14.3%
H
22.3
25.8
|
L
 4.0%
H
21.6
25.8
|
L
 6.9%
H
21.6
27
|
L
 -8.7%
H
21.6
33.5
|
L
 235.9%
H
6.7
34.4
|
L
 178.4%
H
1.0
34.4
|
L
 71.0%
H
1.0
34.4
|
L
H
1.0
34.4
|
| Entrada Therapeutics Inc |
|
261.3
|
6.7
|
L
 1.1%
H
6.7
6.9
|
L
 -4.8%
H
6.5
7.1
|
L
 -11.4%
H
6.3
7.7
|
L
 -5.4%
H
5.7
8.1
|
L
 23.8%
H
5.1
16.5
|
L
 -50.7%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
2,171.3
|
15.2
|
L
 2.4%
H
14.9
15.3
|
L
 -4.1%
H
14.6
15.9
|
L
 -15.1%
H
14.6
18.6
|
L
 -11.5%
H
14.6
20.2
|
L
 87.0%
H
8.0
20.2
|
L
 612.1%
H
1.0
20.2
|
L
 1072.3%
H
0.5
20.2
|
L
H
0.5
20.2
|
| Taysha Gene Therapies Inc |
|
1,681.3
|
5.2
|
L
 2.4%
H
5.1
5.2
|
L
 3.0%
H
4.9
5.5
|
L
 -15.3%
H
4.9
6.3
|
L
 -19.6%
H
4.9
7.1
|
L
 82.3%
H
2.7
7.3
|
L
 70.3%
H
1.1
7.3
|
L
 -72.1%
H
0.5
20.5
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
10,913.2
|
164.6
|
L
 -0.7%
H
162.9
170.7
|
L
 22.2%
H
131.5
170.7
|
L
 13.1%
H
120.2
170.7
|
L
 88.0%
H
80.6
170.7
|
L
 490.2%
H
23.3
170.7
|
L
 736.4%
H
14.4
170.7
|
L
 37.2%
H
11.5
170.7
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
10,514.5
|
80.7
|
L
 2.0%
H
77.5
82.7
|
L
 15.1%
H
70.1
82.7
|
L
 23.9%
H
58.7
82.7
|
L
 132.2%
H
31.3
82.7
|
L
 518.9%
H
11.2
82.7
|
L
 92.6%
H
6.8
82.7
|
L
 -49.9%
H
6.8
187.9
|
L
H
6.8
209.0
|
| Tyra Biosciences Inc |
|
1,758.1
|
25.6
|
L
 -0.3%
H
25.2
26.4
|
L
 2.0%
H
24.2
27.0
|
L
 -1.8%
H
18.7
29.6
|
L
 -9.7%
H
18.7
33.7
|
L
 104.6%
H
12.4
40.7
|
L
 84.8%
H
6.4
40.7
|
L
 29.0%
H
4.9
40.7
|
L
H
4.9
40.7
|
| Unicycive Therapeutics Inc |
|
138.2
|
5.0
|
L
 4.0%
H
4.8
5.0
|
L
 -3.7%
H
4.7
5.2
|
L
 -11.9%
H
4.7
5.6
|
L
 -27.6%
H
3.9
8.6
|
L
 25.3%
H
3.7
8.7
|
L
 -24.8%
H
2.0
18.2
|
L
 -81.1%
H
2.0
31.3
|
L
H
2.0
87.3
|
| TradeUP Acq Corp |
|
-
|
0.5
|
L
 -4%
H
0.5
0.6
|
L
 -25%
H
0.5
0.7
|
L
 -35.1%
H
0.5
0.8
|
L
 -49.5%
H
0.5
1.1
|
L
 -56.8%
H
0.5
3.2
|
L
 -96.9%
H
0.5
15.5
|
L
 -95.1%
H
0.5
33
|
L
H
0.5
33
|
| UroGen Pharma Ltd |
|
2,090.1
|
42.8
|
L
 -1.0%
H
42.6
44.1
|
L
 0.3%
H
41.1
45.3
|
L
 -8.8%
H
41.1
47.2
|
L
 27.4%
H
33.7
50.8
|
L
 138.2%
H
15.9
50.8
|
L
 170.6%
H
3.4
50.8
|
L
 164.9%
H
3.4
50.8
|
L
H
3.4
69.6
|
| United Therapeutics Corp |
|
21,342.0
|
497.6
|
L
 0.9%
H
488.1
499.6
|
L
 -1.0%
H
488.1
507.2
|
L
 -3.0%
H
477.0
531.8
|
L
 -7.3%
H
477.0
563.7
|
L
 19.2%
H
409.1
609.4
|
L
 122.5%
H
208.6
609.4
|
L
 150.3%
H
158.4
609.4
|
L
 303.0%
H
74.3
609.4
|
| Vera Therapeutics Inc (Class A) |
|
2,613.0
|
36.3
|
L
 5.9%
H
34.3
36.5
|
L
 6.5%
H
31.2
37.1
|
L
 12.3%
H
31.2
37.1
|
L
 3.3%
H
28.9
44.9
|
L
 41.7%
H
23.1
56.1
|
L
 143.4%
H
9.2
56.1
|
L
 121.6%
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
1,946.0
|
11.5
|
L
 5.7%
H
10.9
11.7
|
L
 6.9%
H
10.2
11.7
|
L
 17.6%
H
9.4
11.9
|
L
 25.6%
H
8.5
11.9
|
L
 122.0%
H
4.8
11.9
|
L
 25.8%
H
4.2
14.5
|
L
 -77.5%
H
4.2
58
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
1,301.6
|
22
|
L
 0.5%
H
21.6
23.8
|
L
 -4.7%
H
21.2
23.8
|
L
 -5.8%
H
21.2
26
|
L
 51.8%
H
14.2
26
|
L
 -19.2%
H
6.5
50.0
|
L
 909.2%
H
0.1
50.0
|
L
 54.0%
H
0.1
50.0
|
L
H
0.1
63.6
|
| Verastem Inc |
|
758.0
|
8.4
|
L
 4.8%
H
8
8.6
|
L
 11.5%
H
7.2
8.6
|
L
 21.5%
H
6.6
8.6
|
L
 103.2%
H
3.4
8.6
|
L
 -7.5%
H
3.4
10.8
|
L
 -11.9%
H
2.1
14.2
|
L
 -75.6%
H
2.1
39.6
|
L
 -47.9%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
11.1
|
0.3
|
L
 8.7%
H
0.2
0.3
|
L
 4.2%
H
0.2
0.3
|
L
 4.2%
H
0.2
0.3
|
L
 -62.7%
H
0.2
0.8
|
L
 -91.6%
H
0.2
5.1
|
L
 -95.1%
H
0.2
5.9
|
L
 -99.7%
H
0.2
89.4
|
L
 -99.8%
H
0.2
140.7
|
| Voyager Therapeutics Inc |
|
193.5
|
3.1
|
L
 2.0%
H
3.1
3.2
|
L
 -1.6%
H
3.0
3.2
|
L
 -7.4%
H
3.0
3.6
|
L
 -15.6%
H
2.9
3.9
|
L
 -26.5%
H
2.9
5.6
|
L
 -59.4%
H
2.6
11.7
|
L
 4.3%
H
2.5
14.3
|
L
 -77.3%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
624.9
|
6.6
|
L
 -0.5%
H
6.5
6.6
|
L
 -1.2%
H
6.4
6.8
|
L
 -5.3%
H
6.3
7.2
|
L
 22.5%
H
4.8
7.3
|
L
 -35.3%
H
4.8
12.2
|
L
 -49.3%
H
3.6
14.5
|
L
 -77.3%
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
857.2
|
4.4
|
L
 2.1%
H
4.2
4.4
|
L
 -5.0%
H
4.2
4.6
|
L
 -17.8%
H
4.2
5.3
|
L
 -29.4%
H
4.2
6.5
|
L
 -36.9%
H
4.2
21.7
|
L
 -18.8%
H
3.5
21.7
|
L
 -23.4%
H
1.2
21.7
|
L
 -85.1%
H
1.2
56
|
| XBiotech Inc |
|
66.5
|
2.2
|
L
H
2.2
2.2
|
L
 0.5%
H
2.1
2.2
|
L
 -4.4%
H
2.1
2.3
|
L
 -5.6%
H
2.1
2.5
|
L
 -19.9%
H
2.1
3.4
|
L
 -52.2%
H
2.1
10.0
|
L
 -85.8%
H
2.1
16.5
|
L
 -83.4%
H
2.1
26.4
|
| Exicure Inc |
|
8.4
|
1.3
|
L
 2.4%
H
1.2
1.3
|
L
 -5.8%
H
1.2
1.4
|
L
 12.2%
H
1.1
1.6
|
L
 -44.2%
H
1.1
3.2
|
L
 -66.4%
H
1.1
9.5
|
L
 -65.6%
H
0.3
36
|
L
 -99.4%
H
0.3
205.5
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,591.7
|
8.7
|
L
 -0.8%
H
8.6
9.0
|
L
 15.3%
H
7.4
9.0
|
L
 0.3%
H
7.4
9.0
|
L
 25.6%
H
6.9
9.0
|
L
 13.1%
H
5.3
10.1
|
L
 371.9%
H
1.5
10.1
|
L
 259.3%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
340.1
|
3.4
|
L
 -2%
H
3.4
3.6
|
L
 -5.3%
H
3.3
3.7
|
L
 -15.1%
H
3.2
4.4
|
L
 -18.7%
H
3.2
4.8
|
L
 8.2%
H
2.8
4.8
|
L
 226.7%
H
0.2
6.6
|
L
 -34.2%
H
0.2
6.6
|
L
H
0.2
172.2
|
| Xencor Inc |
|
1,870.7
|
25.2
|
L
 0.5%
H
24.9
25.7
|
L
 2.6%
H
23.4
25.7
|
L
 -9.5%
H
23.4
30.6
|
L
 99.1%
H
12.9
30.6
|
L
 144.5%
H
10.0
30.6
|
L
 23.6%
H
6.9
30.6
|
L
 -25.4%
H
6.9
43.6
|
L
 1.7%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
1.3
|
1.8
|
L
 2.3%
H
1.8
1.9
|
L
 -2.2%
H
1.7
1.9
|
L
 -51.9%
H
1.7
4.1
|
L
 -61.0%
H
1.7
5.0
|
L
 -93.9%
H
0.3
32.3
|
L
 -100.0%
H
0.3
842076
|
L
 -100.0%
H
0.3
39346560
|
L
 -100.0%
H
0.3
67850460
|
| Zentalis Pharma Inc |
|
291.6
|
3.1
|
L
 1.7%
H
3.0
3.1
|
L
 -12%
H
3.0
3.5
|
L
 -19.4%
H
3.0
4.2
|
L
 -16.8%
H
3.0
5.6
|
L
 102.6%
H
1.2
7.0
|
L
 -86.1%
H
1.0
22.1
|
L
 -95.3%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
432.2
|
4.5
|
L
 0.2%
H
4.5
4.6
|
L
 -13.4%
H
4.4
5.2
|
L
 -22.9%
H
4.4
7.1
|
L
 20.3%
H
3.8
7.1
|
L
 126.6%
H
2
7.4
|
L
 -26.7%
H
1.0
7.4
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,965.0
|
26.4
|
L
 -0.1%
H
26.4
27.0
|
L
 7.5%
H
24.4
27.1
|
L
 1.5%
H
23.6
27.5
|
L
 45.3%
H
17.2
27.5
|
L
 -19.1%
H
16.0
34.7
|
L
 10.1%
H
13.5
44.3
|
L
 -77.9%
H
13.5
123.3
|
L
H
13.5
193.5
|
| Intensity Therapeutics Inc |
|
13.1
|
4.0
|
L
 -0.3%
H
3.9
4.1
|
L
 0.8%
H
3.8
4.3
|
L
 -17.5%
H
3.8
5.2
|
L
 2.3%
H
3.8
5.2
|
L
 -35.3%
H
3.5
43.5
|
L
 -96%
H
3.5
286
|
L
 -96%
H
3.5
286
|
L
 -96%
H
3.5
286
|
| Renovaro Biosciences Inc |
|
10.1
|
2.2
|
L
 -3.0%
H
2.2
2.7
|
L
 2.8%
H
2.1
2.7
|
L
 3.2%
H
2.1
2.9
|
L
 -41.0%
H
1.9
4.8
|
L
 -84.1%
H
1.2
14.4
|
L
 -99.3%
H
1.2
420
|
L
H
1.2
420
|
L
H
1.2
420
|
| Elutia Inc (Class A) |
|
35.9
|
0.8
|
L
 -4.7%
H
0.8
0.9
|
L
 3.9%
H
0.8
0.9
|
L
 -14.7%
H
0.8
1.1
|
L
 -23.6%
H
0.8
1.1
|
L
 -25.7%
H
0.5
1.4
|
L
 -47.1%
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Dianthus Therapeutics Inc |
|
5,501.1
|
98.4
|
L
 2.0%
H
96.6
100.5
|
L
 -8.7%
H
94.6
108.3
|
L
 -11.5%
H
94.6
113.9
|
L
 19.2%
H
83.9
117.9
|
L
 167.6%
H
32.2
117.9
|
L
 650.2%
H
6.6
117.9
|
L
 12840.8%
H
6.6
117.9
|
L
 12840.8%
H
6.6
117.9
|
| Incannex Healthcare Ltd (ADR) |
|
40.7
|
3.4
|
L
 -2.6%
H
3.4
3.6
|
L
 3.3%
H
3.3
3.8
|
L
 -4.8%
H
3.1
3.9
|
L
 -4.5%
H
2.8
4.0
|
L
 -78.4%
H
2.5
20.3
|
L
 -97.9%
H
2.4
160.2
|
L
 -97.9%
H
2.4
160.2
|
L
 -97.9%
H
2.4
160.2
|
| Canton Strategic Holdings Inc |
|
195.2
|
2.5
|
L
 0.4%
H
2.3
2.5
|
L
 16.7%
H
1.9
2.5
|
L
 11.9%
H
1.9
2.5
|
L
 -26.9%
H
1.8
3.5
|
L
 -31.9%
H
1.8
6.9
|
L
 -97.1%
H
0.3
142.5
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Estrella Biopharma Inc |
|
20.9
|
0.5
|
L
 -4%
H
0.5
0.6
|
L
 -25%
H
0.5
0.7
|
L
 -35.1%
H
0.5
0.8
|
L
 -49.5%
H
0.5
1.1
|
L
 -56.8%
H
0.5
3.2
|
L
 -96.2%
H
0.5
15.5
|
L
 -96.2%
H
0.5
15.5
|
L
 -96.2%
H
0.5
15.5
|
| Lexeo Therapeutics Inc |
|
333.9
|
4.1
|
L
 -0.3%
H
4.0
4.3
|
L
 -3.3%
H
4.0
4.4
|
L
 -16.6%
H
4.0
5.1
|
L
 -17.4%
H
4.0
5.4
|
L
 -21.0%
H
4.0
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Cartesian Therapeutics Inc |
|
244.5
|
8.1
|
L
 1.8%
H
8.0
8.3
|
L
 0.5%
H
7.7
8.3
|
L
 -19.5%
H
7.7
10.9
|
L
 -16.1%
H
7.3
11
|
L
 -14.4%
H
5.6
11
|
L
 -99.1%
H
5.6
1278
|
L
 -99.8%
H
5.6
4076.2
|
L
 -99.9%
H
5.6
25199.6
|
| Elevai Labs Inc |
|
3.4
|
4.3
|
L
 -3.6%
H
4.1
4.5
|
L
 -7.8%
H
4.1
5.1
|
L
 -36.0%
H
4.1
6.9
|
L
 -69.4%
H
4.1
15.6
|
L
 -99.7%
H
4.1
2671.2
|
L
H
4.1
4991179.2
|
L
H
4.1
4991179.2
|
L
H
4.1
4991179.2
|
| Neurogene Inc |
|
672.4
|
33.6
|
L
 3.2%
H
32.8
34.5
|
L
 -4.6%
H
31.2
35.6
|
L
 -13.0%
H
31.2
42.0
|
L
 6.6%
H
29.7
43.7
|
L
 95.4%
H
15.9
43.7
|
L
 137.0%
H
6.9
74.5
|
L
 137.0%
H
6.9
74.5
|
L
 137.0%
H
6.9
74.5
|
| Cg Oncology Inc |
|
6,890.9
|
77.7
|
L
 -0.7%
H
76.3
80.6
|
L
 5.4%
H
72.5
80.6
|
L
 -2.6%
H
70
80.6
|
L
 27.3%
H
61.7
81.0
|
L
 110.7%
H
35.6
81.0
|
L
H
14.8
81.0
|
L
H
14.8
81.0
|
L
H
14.8
81.0
|
| FibroBiologics Inc |
|
9.3
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -13.6%
H
1.3
1.6
|
L
 -6.9%
H
1.3
2.2
|
L
 74.0%
H
0.6
2.2
|
L
 -87.4%
H
0.6
12.4
|
L
H
0.6
1100
|
L
H
0.6
1100
|
L
H
0.6
1100
|
| Alto Neuroscience Inc |
|
1,207.9
|
30.8
|
L
 0.5%
H
30.2
31.5
|
L
 -2.8%
H
29.8
31.7
|
L
 -10.2%
H
29.8
37.5
|
L
 35.4%
H
22.3
37.5
|
L
 755%
H
3.7
37.5
|
L
H
1.6
37.5
|
L
H
1.6
37.5
|
L
H
1.6
37.5
|
| Fractyl Health Inc |
|
87.5
|
0.6
|
L
 -3.5%
H
0.6
0.6
|
L
 -9.8%
H
0.6
0.6
|
L
 -29.5%
H
0.6
0.8
|
L
 -36.1%
H
0.6
1.0
|
L
 -44.4%
H
0.4
2.4
|
L
H
0.4
15
|
L
H
0.4
15
|
L
H
0.4
15
|
| Kyverna Therapeutics Inc |
|
464.4
|
7.5
|
L
 5.5%
H
7.1
7.6
|
L
 1.5%
H
6.9
7.6
|
L
 -10.8%
H
6.9
8.9
|
L
 -6.9%
H
6.9
10.3
|
L
 29.5%
H
5.3
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
43.1
|
1.1
|
L
 1.8%
H
1.1
1.2
|
L
 -4.2%
H
1.1
1.2
|
L
 -7.3%
H
1.1
1.3
|
L
 -5%
H
1.1
1.4
|
L
 -44.4%
H
1.1
4.0
|
L
H
1.1
15
|
L
H
1.1
15
|
L
H
1.1
15
|
| NeOnc Tech Holdings Inc |
|
99.4
|
3.5
|
L
 3.6%
H
3.3
3.5
|
L
 -8.7%
H
3.0
3.8
|
L
 -26.3%
H
3.0
5.2
|
L
 -34.5%
H
3.0
5.8
|
L
 -71.2%
H
3.0
13.0
|
L
H
3.0
13.0
|
L
H
3.0
13.0
|
L
H
3.0
13.0
|
| LENZ Therapeutics Inc |
|
129.8
|
4.1
|
L
 1.2%
H
4.1
4.2
|
L
 -7.6%
H
4
4.4
|
L
 -11.8%
H
4
6.0
|
L
 -32.9%
H
4
6.7
|
L
 -90.2%
H
4
50.4
|
L
 -83.4%
H
4
50.4
|
L
 -83.4%
H
4
50.4
|
L
 -83.4%
H
4
50.4
|
| Boundless Bio Inc |
|
65.5
|
2.9
|
L
 1.8%
H
2.8
2.9
|
L
 1.4%
H
2.8
2.9
|
L
 -4%
H
2.8
3.2
|
L
 101.4%
H
1.4
3.2
|
L
 152.6%
H
1.0
3.2
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
L
H
1.0
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
504.1
|
13.4
|
L
 -1.1%
H
13.2
14
|
L
 -9.6%
H
12.9
14.6
|
L
 -22.1%
H
12.9
17.8
|
L
 12.2%
H
11.4
17.8
|
L
 7.2%
H
8.6
17.8
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
566.9
|
8.6
|
L
 -0.7%
H
8.4
8.8
|
L
 6.3%
H
7.9
8.8
|
L
 27.5%
H
6.3
8.8
|
L
 32.4%
H
5.7
8.8
|
L
 44.0%
H
5.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
L
H
2.2
9.3
|
| GridAI Technologies Corp |
|
27.7
|
3.9
|
L
 14.4%
H
3.4
3.9
|
L
 31.0%
H
2.9
3.9
|
L
 9.0%
H
2.7
4.2
|
L
 -28.0%
H
2.6
5.7
|
L
 -24.6%
H
1.9
6.9
|
L
 -53.4%
H
0.6
9.5
|
L
 -53.4%
H
0.6
9.5
|
L
 -53.4%
H
0.6
9.5
|
| Inhibrx Biosciences Inc |
|
1,628.8
|
110.7
|
L
 -1.2%
H
109.1
117.1
|
L
 0.2%
H
99.1
117.1
|
L
 6.8%
H
94
131.0
|
L
 18.9%
H
77.5
131.0
|
L
 301.0%
H
26.2
155.3
|
L
 797.6%
H
12.2
155.3
|
L
 797.6%
H
12.2
155.3
|
L
 797.6%
H
12.2
155.3
|
| Rapport Therapeutics Inc |
|
1,989.7
|
41.5
|
L
 4.6%
H
37.9
41.6
|
L
 -5.8%
H
37.9
44.0
|
L
 -14.0%
H
37.9
52.9
|
L
 11.1%
H
37.1
52.9
|
L
 57.3%
H
23.8
52.9
|
L
H
6.4
52.9
|
L
H
6.4
52.9
|
L
H
6.4
52.9
|
| Artiva Biotherapeutics Inc |
|
395.5
|
8.1
|
L
 3.3%
H
7.9
8.4
|
L
 -20.2%
H
7.8
10.1
|
L
 -26.0%
H
7.8
12.1
|
L
 -17.6%
H
7.8
12.3
|
L
 180.9%
H
2.5
14.5
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
2,985.0
|
62.0
|
L
 1.7%
H
60.8
63.5
|
L
 4.2%
H
58.4
65
|
L
 -6.6%
H
58.4
69.5
|
L
 44.0%
H
42.0
72.6
|
L
 519.8%
H
12.9
72.6
|
L
H
4.8
72.6
|
L
H
4.8
72.6
|
L
H
4.8
72.6
|
| BioAge Labs Inc |
|
388.3
|
8.5
|
L
 4.6%
H
8.1
8.5
|
L
 -0.2%
H
7.6
8.5
|
L
 -10.8%
H
7.6
10.3
|
L
 -59.3%
H
7.6
26.0
|
L
 72.7%
H
4.9
26.0
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| Voyager Acq Corp (Class A) |
|
44.6
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 -13.5%
H
1.4
1.7
|
L
 -27.7%
H
1.3
2
|
L
 -68.5%
H
1.3
4.5
|
L
 -86.5%
H
1.3
27.4
|
L
H
1.3
27.4
|
L
H
1.3
27.4
|
L
H
1.3
27.4
|
| OnKure Therapeutics Inc (Class A) |
|
125.5
|
3.1
|
L
 1.3%
H
2.9
3.1
|
L
 3.3%
H
2.8
3.1
|
L
 -21.3%
H
2.8
4.4
|
L
 -30.8%
H
2.8
4.8
|
L
 20.6%
H
2.2
5.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
4.2
|
L
 -0.5%
H
3.9
4.2
|
L
 -2.4%
H
3.8
4.4
|
L
 -7.4%
H
3.7
4.6
|
L
 0.5%
H
2.9
6
|
L
 82.0%
H
2.4
7.8
|
L
 80.4%
H
1.3
7.8
|
L
 80.4%
H
1.3
7.8
|
L
 80.4%
H
1.3
7.8
|
| Upstream Bio Inc |
|
300.7
|
5.5
|
L
 2.4%
H
5.4
5.6
|
L
 -5.5%
H
5.2
5.8
|
L
 -21.2%
H
5.2
7.3
|
L
 -12.2%
H
5.2
8
|
L
 -66.5%
H
5.2
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Septerna Inc |
|
1,884.8
|
40.4
|
L
 4.8%
H
38.7
41.1
|
L
 2.1%
H
37.9
41.1
|
L
 1.0%
H
36.0
41.9
|
L
 11.6%
H
30.6
51.1
|
L
 157.2%
H
15.4
51.1
|
L
H
4.2
51.1
|
L
H
4.2
51.1
|
L
H
4.2
51.1
|
| Polyrizon Ltd |
|
25.6
|
10.7
|
L
 -2.2%
H
10.5
11.0
|
L
 -5.8%
H
9.2
11.8
|
L
 3.5%
H
9.2
15.3
|
L
 -20.6%
H
9.1
16.5
|
L
 58.6%
H
2.9
18.2
|
L
H
2.9
7200
|
L
H
2.9
7200
|
L
H
2.9
7200
|
| Medicus Pharma Ltd |
|
11.5
|
0.2
|
L
 -5.9%
H
0.2
0.2
|
L
H
0.2
0.2
|
L
 -40.7%
H
0.1
0.3
|
L
 -65.2%
H
0.1
0.5
|
L
 -94.2%
H
0.1
3.1
|
L
 -97.6%
H
0.1
8.9
|
L
 -97.6%
H
0.1
8.9
|
L
 -97.6%
H
0.1
8.9
|
| Telix Pharma Ltd (ADR) |
|
4,060.4
|
12.0
|
L
 5.7%
H
11.8
12.1
|
L
 1.4%
H
10.8
13.1
|
L
 5.5%
H
10.8
13.1
|
L
 18.4%
H
9.8
13.1
|
L
 19.7%
H
6.3
13.1
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
L
H
6.3
30.4
|
| Palvella Therapeutics Inc |
|
2,278.3
|
158.1
|
L
 3.1%
H
153.6
160.8
|
L
 4.3%
H
148.1
160.8
|
L
 11.3%
H
136.1
160.8
|
L
 39.8%
H
114.6
161.4
|
L
 171.5%
H
56.5
161.4
|
L
 1062.7%
H
11.2
161.4
|
L
 1062.7%
H
11.2
161.4
|
L
 1062.7%
H
11.2
161.4
|
| Zhengye biotech Holding Ltd |
|
60.7
|
1.3
|
L
 -5.2%
H
1.3
1.4
|
L
 -9.9%
H
1.3
1.4
|
L
 -37.3%
H
1.3
2.1
|
L
 70.7%
H
0.6
8.0
|
L
 -86.1%
H
0.6
9.6
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
L
H
0.6
14.3
|
| Sionna Therapeutics Inc |
|
272.2
|
6.0
|
L
 0.3%
H
5.8
6.2
|
L
 -27.1%
H
5.7
8
|
L
 13.8%
H
5.2
8.5
|
L
 -83.9%
H
4.0
55.0
|
L
 -74.0%
H
4.0
55.0
|
L
H
4.0
55.0
|
L
H
4.0
55.0
|
L
H
4.0
55.0
|
| Zenas Biopharma Inc |
|
2,154.1
|
33.1
|
L
 1.5%
H
32.2
33.8
|
L
 3.6%
H
30.3
33.8
|
L
 2.4%
H
29.9
34.0
|
L
 67.1%
H
20.0
34.1
|
L
 74.5%
H
13.5
44.6
|
L
 215.7%
H
8.9
44.6
|
L
 215.7%
H
8.9
44.6
|
L
 215.7%
H
8.9
44.6
|
| Advanced Biomed Inc |
|
10.5
|
6.4
|
L
 -1.4%
H
6.4
6.8
|
L
 -18.0%
H
6.3
8.2
|
L
 -21.6%
H
6.3
10.8
|
L
 25.1%
H
4.1
24.2
|
L
 -31.7%
H
3.6
24.2
|
L
H
3.6
82
|
L
H
3.6
82
|
L
H
3.6
82
|
| Caris Life Sciences Inc (Class A) |
|
8,893.3
|
31.5
|
L
 2.7%
H
31.3
32.4
|
L
 20.8%
H
25.8
32.4
|
L
 19.8%
H
23.2
32.4
|
L
 70.4%
H
15.1
32.4
|
L
 -3.4%
H
14.2
33.7
|
L
 12.4%
H
14.2
42.5
|
L
 12.4%
H
14.2
42.5
|
L
 12.4%
H
14.2
42.5
|
| Propanc Biopharma Inc |
|
1.5
|
0.7
|
L
 3.2%
H
0.6
0.7
|
L
 -23.5%
H
0.6
0.9
|
L
 -39.8%
H
0.6
4.1
|
L
 -55.8%
H
0.6
4.1
|
L
 -98.8%
H
0.6
53.4
|
L
 -99.1%
H
0.6
234
|
L
 -99.1%
H
0.6
234
|
L
 -99.1%
H
0.6
234
|
| SpyGlass Pharma Inc |
|
959.6
|
28.7
|
L
 2.6%
H
27.9
29.1
|
L
 0.1%
H
27
30.0
|
L
 8.2%
H
25.3
30.1
|
L
 53.4%
H
18.4
30.1
|
L
 8.7%
H
17.1
30.6
|
L
 8.7%
H
17.1
30.6
|
L
 8.7%
H
17.1
30.6
|
L
 8.7%
H
17.1
30.6
|
| AgomAb Therapeutics NV ADR |
|
565.9
|
11.5
|
L
 -1.8%
H
11.3
11.8
|
L
 -6.4%
H
11.2
13.0
|
L
 -13.3%
H
11.2
16.5
|
L
 4.6%
H
10.6
17.8
|
L
 -21.6%
H
8.8
17.8
|
L
 -21.6%
H
8.8
17.8
|
L
 -21.6%
H
8.8
17.8
|
L
 -21.6%
H
8.8
17.8
|
| Generate Biomedicines Inc |
|
2,241.0
|
17.5
|
L
 0.5%
H
17.3
18.0
|
L
 9.1%
H
15.6
18.0
|
L
 8.3%
H
14.7
22.7
|
L
 20.5%
H
12.5
22.7
|
L
 38.0%
H
11
22.7
|
L
 38.0%
H
11
22.7
|
L
 38.0%
H
11
22.7
|
L
 38.0%
H
11
22.7
|
| Atrium Therapeutics Inc |
|
157.7
|
9.2
|
L
 0.3%
H
9.2
9.5
|
L
 -9.7%
H
8.7
10.2
|
L
 -30.2%
H
8.7
14.7
|
L
 -27.2%
H
8.7
14.7
|
L
 -37.5%
H
8.7
16.8
|
L
 -37.5%
H
8.7
16.8
|
L
 -37.5%
H
8.7
16.8
|
L
 -37.5%
H
8.7
16.8
|
| Jatt II Acquisition Corp |
|
91.3
|
11.7
|
L
 -4.4%
H
11.6
12.2
|
L
 -3.8%
H
11.6
12.9
|
L
 -11.6%
H
11.5
13.5
|
L
 8.8%
H
10.3
23.8
|
L
 11.4%
H
10
23.8
|
L
 11.4%
H
10
23.8
|
L
 11.4%
H
10
23.8
|
L
 11.4%
H
10
23.8
|
| Kailera Therapeutics Inc |
|
1,658.1
|
12.8
|
L
 6.7%
H
12.1
13.0
|
L
 -7.0%
H
11.8
14.0
|
L
 -25.5%
H
11.8
18.8
|
L
 -35.7%
H
11.8
23.8
|
L
 -50.8%
H
11.8
28.2
|
L
 -50.8%
H
11.8
28.2
|
L
 -50.8%
H
11.8
28.2
|
L
 -50.8%
H
11.8
28.2
|
| Alamar Biosciences Inc |
|
2,305.2
|
33.2
|
L
 -5.2%
H
32.5
35.5
|
L
 18.7%
H
27.9
37.8
|
L
 -3.0%
H
27.3
37.8
|
L
 51.3%
H
21.6
38.5
|
L
 51%
H
18.8
38.5
|
L
 51%
H
18.8
38.5
|
L
 51%
H
18.8
38.5
|
L
 51%
H
18.8
38.5
|
| LakewoodAmedex |
|
4.7
|
2.0
|
L
 -2.9%
H
1.9
2.1
|
L
 -6.1%
H
1.8
2.2
|
L
 -11.2%
H
1.8
2.9
|
L
 -48.5%
H
1.7
6.9
|
L
 -97.7%
H
1.7
94
|
L
 -97.7%
H
1.7
94
|
L
 -97.7%
H
1.7
94
|
L
 -97.7%
H
1.7
94
|
| Hemab Therapeutics Holdings |
|
1,786.7
|
38.3
|
L
 0.7%
H
37.4
39.8
|
L
 -5.5%
H
37.4
44.0
|
L
 -22.2%
H
37.4
52
|
L
 30.8%
H
27.5
55.4
|
L
 12.5%
H
23
55.4
|
L
 12.5%
H
23
55.4
|
L
 12.5%
H
23
55.4
|
L
 12.5%
H
23
55.4
|
| Odyssey Therapeutics Inc |
|
1,121.7
|
23.3
|
L
 1.2%
H
22.7
24.3
|
L
 -3.8%
H
21.7
25.8
|
L
 -11.6%
H
21.7
29.1
|
L
 22.4%
H
15.1
29.1
|
L
 42.1%
H
15.1
29.1
|
L
 42.1%
H
15.1
29.1
|
L
 42.1%
H
15.1
29.1
|
L
 42.1%
H
15.1
29.1
|
| Lakefront Biotherapeutics NV |
|
1,977.0
|
30.2
|
L
 2.0%
H
29.6
30.3
|
L
 13.0%
H
26.6
30.3
|
L
 4.8%
H
26.6
30.3
|
L
 6.7%
H
25.7
30.9
|
L
 5.6%
H
25.7
30.9
|
L
 5.6%
H
25.7
30.9
|
L
 5.6%
H
25.7
30.9
|
L
 5.6%
H
25.7
30.9
|
| Conexeu Sciences Inc |
|
124.1
|
4.4
|
L
 -7.4%
H
4.4
4.9
|
L
 -12%
H
4.4
5.5
|
L
 -50.5%
H
4.2
9.2
|
L
 -66.9%
H
4.2
13.7
|
L
 -66.3%
H
4.2
18.8
|
L
 -66.3%
H
4.2
18.8
|
L
 -66.3%
H
4.2
18.8
|
L
 -66.3%
H
4.2
18.8
|
| Veraxa Biotech AG |
|
199.4
|
1.4
|
L
 -0.7%
H
1.4
1.4
|
L
 -13.5%
H
1.4
1.7
|
L
 -27.7%
H
1.3
2
|
L
 -68.5%
H
1.3
4.5
|
L
 -94.3%
H
1.3
26.0
|
L
 -94.3%
H
1.3
26.0
|
L
 -94.3%
H
1.3
26.0
|
L
 -94.3%
H
1.3
26.0
|
| Kardigan Inc |
|
1,537.2
|
16.4
|
L
 0.9%
H
16.1
16.6
|
L
 -13.7%
H
15.9
19.1
|
L
 -21.8%
H
15.9
22.5
|
L
 -25.3%
H
15.9
27
|
L
 -25.3%
H
15.9
27
|
L
 -25.3%
H
15.9
27
|
L
 -25.3%
H
15.9
27
|
L
 -25.3%
H
15.9
27
|
| Braveheart Bio Inc |
|
2,125.8
|
23.6
|
L
 -5.6%
H
23.4
25.4
|
L
 -12.6%
H
23.4
29.5
|
L
 -14.4%
H
23.4
30.0
|
L
 -20.8%
H
23.4
32
|
L
 -20.8%
H
23.4
32
|
L
 -20.8%
H
23.4
32
|
L
 -20.8%
H
23.4
32
|
L
 -20.8%
H
23.4
32
|
| BioStem Technologies Inc |
|
71.4
|
4.0
|
L
 -9.6%
H
4.0
4.6
|
L
 -5.5%
H
3.9
5.4
|
L
 12.4%
H
3.4
5.4
|
L
 -2.7%
H
2.3
5.4
|
L
 -2.7%
H
2.3
5.4
|
L
 -2.7%
H
2.3
5.4
|
L
 -2.7%
H
2.3
5.4
|
L
 -2.7%
H
2.3
5.4
|
| Vogenx Inc |
|
369.5
|
26.6
|
L
 -9.9%
H
24.1
28.9
|
L
 -18.0%
H
24.1
38.4
|
L
 -10.0%
H
24.1
38.4
|
L
 104.4%
H
13
38.4
|
L
 104.4%
H
13
38.4
|
L
 104.4%
H
13
38.4
|
L
 104.4%
H
13
38.4
|
L
 104.4%
H
13
38.4
|